<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Behav Neurol</journal-id>
<journal-id journal-id-type="iso-abbrev">Behav Neurol</journal-id>
<journal-id journal-id-type="publisher-id">BN</journal-id>
<journal-title-group>
<journal-title>Behavioural Neurology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0953-4180</issn>
<issn pub-type="epub">1875-8584</issn>
<publisher>
<publisher-name>Hindawi</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30581496</article-id>
<article-id pub-id-type="pmc">6276511</article-id>
<article-id pub-id-type="doi">10.1155/2018/2064027</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Mechanisms Underlying Aggressive Behavior Induced by Antiepileptic Drugs: Focus on Topiramate, Levetiracetam, and Perampanel</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Hansen</surname>
<given-names>Cerine C.</given-names>
</name>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ljung</surname>
<given-names>Hanna</given-names>
</name>
<xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brodtkorb</surname>
<given-names>Eylert</given-names>
</name>
<xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref>
<xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-6286-554X</contrib-id>
<name>
<surname>Reimers</surname>
<given-names>Arne</given-names>
</name>
<email>arne.reimers@med.lu.se</email>
<xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref>
<xref ref-type="aff" rid="I7">
<sup>7</sup>
</xref>
</contrib>
</contrib-group>
<aff id="I1">
<sup>1</sup>Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway</aff>
<aff id="I2">
<sup>2</sup>Department of Neurology and Rehabilitation Medicine, Skåne University Hospital, Lund, Sweden</aff>
<aff id="I3">
<sup>3</sup>Department of Clinical Neurosciences Lund, Faculty of Medicine, Lund University, Lund, Sweden</aff>
<aff id="I4">
<sup>4</sup>Department of Neurology and Clinical Neurophysiology, St. Olavs University Hospital, Trondheim, Norway</aff>
<aff id="I5">
<sup>5</sup>Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway</aff>
<aff id="I6">
<sup>6</sup>Department of Clinical Chemistry and Pharmacology, Skåne University Hospital, Lund, Sweden</aff>
<aff id="I7">
<sup>7</sup>Division of Clinical Chemistry and Pharmacology, Lund University, Lund, Sweden</aff>
<author-notes>
<fn fn-type="other">
<p>Academic Editor: Guido Rubboli</p>
</fn>
</author-notes>
<pub-date pub-type="collection">
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>15</day>
<month>11</month>
<year>2018</year>
</pub-date>
<volume>2018</volume>
<elocation-id>2064027</elocation-id>
<history>
<date date-type="received">
<day>21</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>10</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2018 Cerine C. Hansen et al.</copyright-statement>
<copyright-year>2018</copyright-year>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>Antiepileptic drugs (AEDs) are effective against seizures, but their use is often limited by adverse effects, among them psychiatric and behavioral ones including aggressive behavior (AB). Knowledge of the incidence, risk factors, and the underlying mechanisms of AB induced by AEDs may help to facilitate management and reduce the risk of such side effects. The exact incidence of AB as an adverse effect of AEDs is difficult to estimate, but frequencies up to 16% have been reported. Primarily, levetiracetam (LEV), perampanel (PER), and topiramate (TPM), which have diverse mechanisms of action, have been associated with AB. Currently, there is no evidence for a specific pharmacological mechanism solely explaining the increased incidence of AB with LEV, PER, and TPM. Serotonin (5-HT) and GABA, and particularly glutamate (via the AMPA receptor), seem to play key roles. Other mechanisms involve hormones, epigenetics, and “alternative psychosis” and related phenomena. Increased individual susceptibility due to an underlying neurological and/or a mental health disorder may further explain why people with epilepsy are at an increased risk of AB when using AEDs. Remarkably, AB may occur with a delay of weeks or months after start of treatment. Information to patients, relatives, and caregivers, as well as sufficient clinical follow-up, is crucial, and there is a need for further research to understand the complex relationship between AED mechanisms of action and the induction/worsening of AB.</p>
</abstract>
</article-meta>
</front>
<body>
<sec id="sec1">
<title>1. Introduction</title>
<p>With a prevalence of about 0.6–0.7% in developed countries, epilepsy is the fourth most common neurologic disease after migraine, Alzheimer's disease, and stroke [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>]. Most patients receive treatment with antiepileptic drugs (AEDs), and up to 70% of them become seizure-free [<xref ref-type="bibr" rid="B3">3</xref>]. However, AEDs are potent agents that can induce numerous adverse reactions and drug-drug interactions. Psychiatric and behavioral adverse reactions (PBAR) are common. They include depression, anxiety, psychosis, and aggressive behavior (AB) [<xref ref-type="bibr" rid="B4">4</xref>]. In everyday practice, the numerous clinical expressions of AED-induced PBAR may be difficult to distinguish from endogenous clinical manifestations in the individual patient.</p>
<p>Levetiracetam (LEV), perampanel (PER), and topiramate (TPM) are currently identified as AEDs with the strongest evidence for AB. However, benzodiazepines, brivaracetam (BRV), phenobarbital, tiagabine, vigabatrin, and zonisamide are also associated with a higher occurrence of AB compared to other AEDs [<xref ref-type="bibr" rid="B4">4</xref>]. The risk is increased in patients with a previous history of psychiatric disorders [<xref ref-type="bibr" rid="B4">4</xref>–<xref ref-type="bibr" rid="B6">6</xref>]. This kind of adverse effect can become a significant clinical problem since these AEDs often are used in difficult-to treat epilepsy. When improved seizure control is achieved with these drugs, the occurrence of intolerable PBAR necessitating discontinuation of the effective drug is highly unfortunate.</p>
<p>It is unclear which pharmacological mechanisms evoke AB. Eventually, multiple mechanisms of action (MOAs) have been identified for most AEDs. Despite this, AEDs are usually classified according to their proposed “main” or “principal” MOA, although such categorization is of limited clinical value. This is illustrated by the observation that AEDs with different principal MOAs can have identical therapeutic effects, while AEDs with a similar principal MOA can have divergent therapeutic effects. Likewise, AEDs with different principal MOAs can induce identical adverse effects, while AEDs with an identical principal MOA may have different safety profiles.</p>
<p>LEV, PER, and TPM have divergent pharmacological profiles with several different MOAs. Yet, they can all induce AB. While LEV and PER have been assigned a principal MOA, TPM has been actively marketed as a “multiple-MOA” AED.</p>
<p>These three main culprit drugs will be used as models to discuss established knowledge as well as various hypotheses about AB as an adverse effect of AEDs. Three main questions will be addressed:
<list list-type="order"><list-item><p>Which MOAs can induce AB?</p></list-item><list-item><p>Do these AEDs (LEV, PER, and TPM) have a common MOA that is responsible for this particular adverse effect?</p></list-item><list-item><p>Could AB be an indirect effect, i.e., the consequence of the clinical efficacy of these AEDs?</p></list-item></list></p>
<p>This review is based on searches in various online repositories (PubMed, ResearchGate, Google Scholar, and EMBASE) using «antiepileptic drugs», «levetiracetam», «perampanel» and «topiramate», combined with terms such as «behavior», «psychiatric side effects», «aggression», «agitation», «irritability», and «adverse effect». The searches included publications until February 2018.</p>
</sec>
<sec id="sec2">
<title>2. Aggressive Behavior: Epidemiology, Etiology, and Treatment</title>
<p>It is well-documented that the prevalence of psychiatric conditions is higher in people with epilepsy than in the general population. It is estimated that as much as 30% of newly diagnosed and 50% of treatment-resistant patients have a psychiatric disorder, mainly depression, anxiety, and psychosis [<xref ref-type="bibr" rid="B7">7</xref>]. It may therefore be assumed that AB is common in people with epilepsy. However, the actual prevalence is not known [<xref ref-type="bibr" rid="B8">8</xref>].</p>
<p>Aggression is a social behavior that is aimed at eliciting discomfort, pain, or physical damage, to oneself, to another person, or to things or at defending oneself against a threat. AB can be defensive, instrumental (planned with the intention of achieving a goal), or impulsive (in anger and after provocation) [<xref ref-type="bibr" rid="B4">4</xref>].</p>
<p>AB can occur as a symptom of various medical conditions such as brain damage, encephalitis, drug use, dementia, intoxication, psychosis, affective disorders, and personality disorders as well as in relational, behavioral, developmental, and adaptational disorders [<xref ref-type="bibr" rid="B9">9</xref>]. This implies that AB occurs not only as a permanent personality trait but also as a temporary behavior change. It is estimated that up to 60% of people with intellectual disability exhibit signs of AB [<xref ref-type="bibr" rid="B10">10</xref>].</p>
<p>The heterogeneity of AB suggests a complex etiology [<xref ref-type="bibr" rid="B11">11</xref>]. Indeed, AB has been associated with genetic, epigenetic, neurobiological, and psychosocial factors [<xref ref-type="bibr" rid="B12">12</xref>]. Several cortical and subcortical brain networks are involved, predominantly those mainly modulated by the monoamines serotonin (5-HT), dopamine (DA), and norepinephrine (NE), but also glutamate and gamma-amino-butyric acid (GABA) play an important role. Dysregulation of several proteins in these networks contribute to AB. These include 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors, 5-HT transporters, DA D<sub>1</sub> and D<sub>2</sub> receptors, DA transporters, <italic>α</italic>1 and <italic>α</italic>2 adrenoceptors, monoaminoxidase (MAO) A, GABA<sub>A</sub> and GABA<sub>B</sub> receptors, GABA transaminase, glutamatergic N-methyl-D-aspartate (NMDA), and <italic>α</italic>-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, as well as voltage-regulated sodium and calcium channels [<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>].</p>
<p>Other neuroactive substances may also interact with these networks, e.g., steroid hormones, vasopressin, histamine, substance P, nitrogen monoxide (NO), neural cell adhesion molecule (NCAM), and interleukins [<xref ref-type="bibr" rid="B14">14</xref>]. Imaging studies have identified brain structures that are associated with AB, such as the prefrontal cortex, amygdala, hypothalamus, hippocampus, septal nuclei, and periaqueductal gray matter (PAG) [<xref ref-type="bibr" rid="B12">12</xref>].</p>
<p>Treatment of AB is versatile, including drugs and nonpharmacological interventions. Because of the diverse and complex etiology, as well as different comorbidities, the choice of intervention and type of drug treatment may vary considerably between individual patients. AB in conjunction with acute psychosis or mild depression, for instance, needs different treatment approaches [<xref ref-type="bibr" rid="B11">11</xref>]. A plethora of drugs may be used to treat AB. Second-generation antipsychotic drugs have been used, based on their ability to modulate several receptors involved in AB, such as 5-HT, DA, NMDA, NE, and GABA receptors [<xref ref-type="bibr" rid="B13">13</xref>]. Benzodiazepines, being allosteric agonists at GABA<sub>A</sub> receptors, have also been used. However, they may elicit paradoxical reactions, i.e., reinforced AB [<xref ref-type="bibr" rid="B12">12</xref>]. Selective serotonin reuptake inhibitors (SSRI), <italic>β</italic>-adrenergic blockers, psychostimulants (e.g., amphetamine), lithium, and AEDs like valproate, lamotrigine, gabapentin, and TPM have all been shown to be effective [<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B13">13</xref>]. Nevertheless, the most promising treatments will be those that take underlying, specific processes into consideration [<xref ref-type="bibr" rid="B11">11</xref>].</p>
</sec>
<sec id="sec3">
<title>3. Aggressive Behavior as an Adverse Effect of AEDs</title>
<p>It has been estimated that up to 50% of AED users experience adverse reactions, leading to discontinuation of the culprit drug in up to 20% of all cases [<xref ref-type="bibr" rid="B15">15</xref>–<xref ref-type="bibr" rid="B17">17</xref>]. Generally, most newer AEDs have better tolerability profiles than the older ones [<xref ref-type="bibr" rid="B17">17</xref>]. Many adverse effects are dose-dependent and often involve the central nervous system, such as dizziness, sedation, ataxia, nystagmus, and impaired cognitive functions.</p>
<p>AEDs may frequently induce PBAR, including depression, anxiety, psychosis, and AB. The prevalence of such adverse effects in adults with epilepsy has been estimated to be 8–20% [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B18">18</xref>] and 11–14% in patients ≤ 18 years [<xref ref-type="bibr" rid="B19">19</xref>]. It can be difficult to distinguish between psychiatric adverse effects that are induced by AEDs and preexisting traits that are worsened by AEDs, since such conditions are common in people with epilepsy [<xref ref-type="bibr" rid="B20">20</xref>]. LEV, PER, and TPM are associated with the highest reported frequency of AB among AEDs, particularly in patients with a previous history of psychiatric symptoms [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B20">20</xref>, <xref ref-type="bibr" rid="B21">21</xref>]. The recently introduced BRV, which is chemically closely related to LEV, is said to have less potential to induce behavioral side effects than LEV [<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>]. However, no studies that directly compare LEV and BRV have been published. In children and adolescents, there is also an increased risk of AB associated with gabapentin, phenobarbital, valproate, and zonisamide [<xref ref-type="bibr" rid="B4">4</xref>]. Predisposing endogenous factors are previous psychiatric condition, frontal lobe epilepsy, absence epilepsy, and difficult-to-treat (“treatment-resistant”) epilepsy [<xref ref-type="bibr" rid="B19">19</xref>].</p>
<p>
<xref ref-type="table" rid="tab1">Table 1</xref> provides an overview of various PBAR of LEV, PER, and TPM and their frequencies. Aggression and irritability are categorized as “common” adverse effects in their respective summary of product characteristics (SPC), meaning that they occur with a frequency of 1–10% [<xref ref-type="bibr" rid="B24">24</xref>–<xref ref-type="bibr" rid="B26">26</xref>]. Some studies report even higher frequencies, e.g., up to 16% for LEV [<xref ref-type="bibr" rid="B27">27</xref>]. TPM on the other hand shows the broadest spectrum of PBAR, including anxiety, agitation, aggression, depression, and psychosis [<xref ref-type="bibr" rid="B28">28</xref>]. The SPC for BRV states irritability as common and aggression as uncommon [<xref ref-type="bibr" rid="B29">29</xref>]. However, newer studies report higher frequencies, although still lower than for LEV [<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>].</p>
<p>It is difficult to predict at which point in time PBAR will become manifest, since data from clinical studies are scarce and not uniform (Tables <xref ref-type="table" rid="tab2">2</xref><xref ref-type="table" rid="tab3"></xref>–<xref ref-type="table" rid="tab4">4</xref>). Most studies merely report that PBAR occurred during the study period, and only a few studies state a time interval from start of treatment until the adverse effect emerged. Dinkelacker et al. [<xref ref-type="bibr" rid="B30">30</xref>] report an interval of 3.6 months from start with LEV to the recognition of PBAR. Similarly, Mula et al. [<xref ref-type="bibr" rid="B31">31</xref>] report an average delay of 88 days for mainly aggression, agitation, anger, and hostile behavior. Other studies state a much shorter interval of less than one month [<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B33">33</xref>]. For PER, various time intervals have been reported: within six weeks [<xref ref-type="bibr" rid="B34">34</xref>], three months [<xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>], or even six months [<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>]. For TPM, Mula et al. [<xref ref-type="bibr" rid="B38">38</xref>] state an interval of 60 days for the emergence of affective disorders and aggression, even later for psychosis. However, it is difficult to sort out to what extent the delayed reactions might be associated with a gradual dose increase.</p>
<p>People with epilepsy seem to be more susceptible to PBARs from AEDs, particularly LEV and PER, since the prevalence of such reactions is lower when these drugs are used for non-epilepsy conditions (Tables <xref ref-type="table" rid="tab2">2</xref> and <xref ref-type="table" rid="tab3">3</xref>) [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B21">21</xref>]. Moreover, some data suggest that the incidence and clinical characteristics of AB depend not only on previous psychiatric history but also on age, sex, type of epilepsy, and AED dose [<xref ref-type="bibr" rid="B28">28</xref>]. This is discussed in <xref ref-type="sec" rid="sec5">Section 5</xref>.</p>
<p>Adverse reactions involving the CNS are often, but not always, dose-dependent, and it seems that the risk for PBAR can be reduced by low initial doses and slow titration [<xref ref-type="bibr" rid="B39">39</xref>–<xref ref-type="bibr" rid="B42">42</xref>]. This applies particularly to PER, since many studies found that adverse effects primarily occur with doses of 8 or 12 mg/day. In phase III clinical studies, the overall rate of psychiatric TEAEs was 17.2% (8 mg) and 22.4% (12 mg) (placebo: 12.4%) [<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B43">43</xref>–<xref ref-type="bibr" rid="B48">48</xref>]. Regarding LEV, the literature is more diverse. Some studies suggest that adverse reactions to LEV are mostly dose-independent, as they may occur at any dose and despite slow titration, while others found that the likelihood of LEV being discontinued or lowered was higher when it was initiated at a high dose [<xref ref-type="bibr" rid="B49">49</xref>–<xref ref-type="bibr" rid="B53">53</xref>]. With TPM, slow titration may reduce the risk, although adverse reactions may occur at any dose. PBAR induced by TPM usually resolve upon dose reduction [<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B50">50</xref>, <xref ref-type="bibr" rid="B54">54</xref>–<xref ref-type="bibr" rid="B56">56</xref>].</p>
</sec>
<sec id="sec4">
<title>4. Possible Neuropharmacological Mechanisms of AED-Induced Aggressive Behavior</title>
<sec id="sec4.1">
<title>4.1. Levetiracetam</title>
<p>Levetiracetam (LEV) is effective in focal onset seizures as well as in generalized onset tonic-clonic and myoclonic seizures [<xref ref-type="bibr" rid="B24">24</xref>]. LEV is a pyrrolidone derivative that has been developed from piracetam. It is presumed to act on presynaptic neurotransmitter release by binding to synaptic vesicle protein 2A (SV2A), a glycoprotein that is part of the membrane of presynaptic neurotransmitter-containing vesicles in neurons and neuroendocrine cells. SV2A and related isoforms (SV2B, SV2C) are expressed in several locations in the brain, especially in the cortex but also in subcortical regions such as thalamus, basal ganglia, and hippocampus. Reduced expression of SV2A may lead to a lower seizure threshold and epileptogenesis [<xref ref-type="bibr" rid="B84">84</xref>].</p>
<p>It is not clear exactly how LEV's binding to SV2A results in antiepileptic efficacy, but it is assumed that this protein is involved in exocytosis of neurotransmitters and that this exocytosis is downregulated either via reduced calcium inward currents or other modulating mechanisms [<xref ref-type="bibr" rid="B85">85</xref>]. The recently introduced AED, BRV, is a derivative of LEV/piracetam and has a higher affinity to SV2A, although it has already been shown that BRV also acts as a sodium channel blocker [<xref ref-type="bibr" rid="B86">86</xref>].</p>
<p>LEV also increases tissue concentrations of GABA, neutralizes the action of negative modulators of the GABA<sub>A</sub> receptor, and reduces the excitatory action of glutamate by modulation of AMPA receptors [<xref ref-type="bibr" rid="B84">84</xref>, <xref ref-type="bibr" rid="B87">87</xref>–<xref ref-type="bibr" rid="B92">92</xref>]. Several studies suggest that LEV modulates neuronal cell function via additional pharmacological mechanisms including modulation of serotonergic and <italic>α</italic>2-adrenergic signaling paths as well as <italic>μ</italic>-opioid receptors [<xref ref-type="bibr" rid="B93">93</xref>]. LEV also modulates intraneuronal calcium levels via inhibition of N-type calcium channels. Other MOAs associated with LEV are modulation of presynaptic P/Q-type calcium channels and potassium channels, as well as upregulation of glutamate transporters in glial cells [<xref ref-type="bibr" rid="B84">84</xref>, <xref ref-type="bibr" rid="B91">91</xref>, <xref ref-type="bibr" rid="B94">94</xref>]. It is not clear whether these MOAs occur on their own or as a consequence of the interaction with SV2A [<xref ref-type="bibr" rid="B84">84</xref>, <xref ref-type="bibr" rid="B93">93</xref>].</p>
<p>The broad pharmacological effect of LEV makes it difficult to determine the exact cause of AB. The high rate of AB with LEV may not necessarily be related to SV2A, since it has been suggested that BRV, which has a 15–30 times higher affinity to SV2A than LEV, is associated with a lower incidence of AB than LEV [<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B95">95</xref>]. Interestingly, it seems that BRV does not modulate NMDA, AMPA, or kainate receptors [<xref ref-type="bibr" rid="B96">96</xref>, <xref ref-type="bibr" rid="B97">97</xref>]. These findings suggest that LEV's negative modulating effect on AMPA receptors contributes to increased AB. This idea is supported by the observation that piracetam (the predecessor of LEV) is not associated with increased AB. Piracetam improves neural and cognitive functions, presumably via positive allosteric modulation of the AMPA receptor [<xref ref-type="bibr" rid="B98">98</xref>, <xref ref-type="bibr" rid="B99">99</xref>]. The interaction between NMDA and AMPA receptors and AB is discussed in more detail under <xref ref-type="sec" rid="sec4.2">Section 4.2</xref>.</p>
<p>5-HT (serotonin) and GABA have also been associated with AB [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B100">100</xref>]. 5-HT is possibly the best-studied neurotransmitter in relation to AB, especially impulsive aggression [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B100">100</xref>, <xref ref-type="bibr" rid="B101">101</xref>]. Several studies suggest that 5-HT modulates brain activity in the prefrontal cortex, which controls limbic system responses to stimuli, i.e., regulation of emotions. It has been speculated that reduced levels of 5-HT and its metabolite 5-hydroxyindoleacetate (5-HIAA) are associated with impulsive aggression [<xref ref-type="bibr" rid="B101">101</xref>, <xref ref-type="bibr" rid="B102">102</xref>]. However, the relationship between 5-HT and behavior is complex [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B101">101</xref>]. The 5-HT-system consists of at least 14 different receptors with subtypes, both pre- and postsynaptic, with unique and partly antagonistic effects on aggression [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B101">101</xref>]. Undoubtedly, 5-HT is involved in AB, but whether LEV might interfere with this mechanism is unclear. The relationship between GABA and AB is discussed under <xref ref-type="sec" rid="sec4.3">Section 4.3</xref>.</p>
</sec>
<sec id="sec4.2">
<title>4.2. Perampanel</title>
<p>Perampanel (PER) is licensed as add-on treatment for focal onset seizures and generalized onset tonic-clonic seizures in patients &gt; 12 years [<xref ref-type="bibr" rid="B25">25</xref>]. It acts as a highly selective, noncompetitive antagonist on AMPA receptors, thereby reducing glutamatergic transmission. In contrast to competitive antagonists, noncompetitive antagonists will not be overcome by high synaptic glutamate concentrations. PER reduces calcium inward currents through AMPA receptors in cortical and subcortical brain regions. Some data suggest that it also acts on NMDA and kainate receptors [<xref ref-type="bibr" rid="B103">103</xref>]. PER is one of the newest AEDs, and presently, there is no evidence that it acts on other pharmacological targets.</p>
<p>Increased levels of glutamate are associated with increased AB, particularly impulsive aggression [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B104">104</xref>]. This is believed to be mediated by stimulation of glutamatergic receptors in the amygdala, hypothalamus, and periaqueductal gray matter [<xref ref-type="bibr" rid="B104">104</xref>]. Genetic modification of AMPA and NMDA receptors in mice leads to changes in AB [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B104">104</xref>–<xref ref-type="bibr" rid="B106">106</xref>]. However, glutamate's effect on behavior is complex and studies demonstrated that blocking of AMPA receptors can both decrease and increase AB [<xref ref-type="bibr" rid="B106">106</xref>, <xref ref-type="bibr" rid="B107">107</xref>]. It has been demonstrated that phencyclidine, a NMDA antagonist, increases aggression at low doses, but decreases it at higher doses [<xref ref-type="bibr" rid="B108">108</xref>].</p>
</sec>
<sec id="sec4.3">
<title>4.3. Topiramate</title>
<p>Topiramate (TPM) is effective against focal onset seizures and generalized onset tonic-clonic seizures [<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B109">109</xref>]. Additionally, it is effective as a prophylactic treatment of migraine [<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B109">109</xref>]. Topiramate has several MOAs. While none of them has been pointed out as the principal MOA, three of them have received most attention: blockade of voltage-dependent sodium and calcium channels, enhancement of GABA-dependent chloride inward currents, and antagonism at glutamatergic AMPA and kainate receptors [<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B109">109</xref>, <xref ref-type="bibr" rid="B110">110</xref>]. These channels and receptors are all involved in aggressive behavior [<xref ref-type="bibr" rid="B4">4</xref>]. TPM also inhibits carbonic anhydrase types II and IV, although this MOA is not believed to contribute noteworthy to TPM's antiepileptic effect [<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B110">110</xref>]. Some studies have shown that TPM has neuroprotective properties [<xref ref-type="bibr" rid="B111">111</xref>]. Being a fructose derivative, TPM is structurally unrelated to other AEDs (although it shares with zonisamide a sulfamate group) [<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B109">109</xref>, <xref ref-type="bibr" rid="B110">110</xref>].</p>
</sec>
<sec id="sec4.4">
<title>4.4. One Common Mechanism?</title>
<p>Having reviewed the different pharmacological profiles of LEV, TPM, and PER, it is still not possible to conclude with certainty which MOA is responsible for the increased rate of AB in people treated with these drugs. Available data suggest that 5-HT, glutamate, and GABA play a major role in AB. Since all three AEDs have an inhibiting effect on glutamatergic transmission via the AMPA receptor, it appears most promising for future research to focus on this mechanism [<xref ref-type="bibr" rid="B18">18</xref>]. One caveat is that these MOAs are only the ones that we are currently aware of, but this may change. It cannot be ruled out that LEV, PER, and TPM exert part or most of their therapeutic and undesired effects via other MOAs that have not been discovered yet.</p>
</sec>
</sec>
<sec id="sec5">
<title>5. Biological Vulnerability</title>
<p>A wide range of clinical factors may interact to lay the ground for the development of AB induced by AEDs.</p>
<sec id="sec5.1">
<title>5.1. The Epileptic Disorder Itself</title>
<p>Neurological and psychiatric conditions may generally increase the vulnerability for PBAR [<xref ref-type="bibr" rid="B67">67</xref>]. This is in line with the observation that the rate of PBAR is lower in patients using AEDs for non-epilepsy conditions [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B21">21</xref>]. It has been speculated that the increased vulnerability is due to structural and functional cerebral alterations.</p>
<p>Generalized onset seizures, particularly absence seizures, are associated with an increased risk of psychiatric and behavior-related symptoms, including anger, irritability, and aggression [<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B24">24</xref>, <xref ref-type="bibr" rid="B53">53</xref>]. It has been suggested that absence seizures have a cortical origin in the frontal lobe and involve the thalamus which may cause general functional impairment. These brain regions are associated with regulation of aggressive behavior [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B112">112</xref>].</p>
<p>Juvenile myoclonic epilepsy (JME) is the most common form of idiopathic generalized epilepsy. It is associated with personality disorders, psychosocial maladjustment, and psychiatric comorbidity including substance and alcohol abuse [<xref ref-type="bibr" rid="B113">113</xref>, <xref ref-type="bibr" rid="B114">114</xref>]. Impulsiveness, quick and frequent mood changes, and risk-seeking behavior are reported in a subset of these patients [<xref ref-type="bibr" rid="B114">114</xref>]. Executive functions, e.g., problem-solving, planning, execution of tasks, and behavioral control, are often impaired. This has been associated with frontal lobe dysfunction, as suggested by neuropsychological testing and advanced imaging [<xref ref-type="bibr" rid="B113">113</xref>, <xref ref-type="bibr" rid="B114">114</xref>]. It seems that patients with JME are more vulnerable for PBAR induced by AEDs [<xref ref-type="bibr" rid="B113">113</xref>]. However, the clinical heterogeneity is pronounced, and psychosocial outcome and treatment responses vary widely in JME [<xref ref-type="bibr" rid="B114">114</xref>].</p>
<p>Besides generalized epilepsy, temporal lobe epilepsy (TLE) as well is associated with psychiatric symptoms, including aggression [<xref ref-type="bibr" rid="B4">4</xref>]. The medial part of the temporal lobe contributes to the regulation of emotions by its connection to the limbic system. Structural or functional abnormalities in the medial temporal lobe, like neuronal loss, synaptic reorganization, or changes in the hippocampus or the amygdala, are associated with a disposition for the development of AB [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B115">115</xref>]. A previous history of febrile seizures or status epilepticus is often involved [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B115">115</xref>]. Brodie et al. [<xref ref-type="bibr" rid="B4">4</xref>] suggest that the structural changes seen with TLE may lead to growth of immature GABAergic neurons that convey excitation instead of inhibition, as seen in the brain of newborns. Hence, AEDs that reinforce GABA, i.e., LEV or TPM, would increase neuronal excitement instead of decreasing it [<xref ref-type="bibr" rid="B4">4</xref>]. Similar paradoxical effects may take place in the glutamatergic system, which implies that AEDs that normally inhibit glutamatergic signal transmission (LEV, PER, and TPM) might instead have a facilitating effect [<xref ref-type="bibr" rid="B4">4</xref>]. How these changes might affect the propensity to PBAR is not clear.</p>
</sec>
<sec id="sec5.2">
<title>5.2. Psychiatric Comorbidity</title>
<p>The relationship between structural anomalies in the brain and PBAR is further illustrated by the fact that AB is frequently seen in patients with central nervous pathology, e.g., due to trauma or infection [<xref ref-type="bibr" rid="B116">116</xref>]. The concept of the interictal dysphoric disorder means that patients with epilepsy may exhibit the following psychiatric symptoms between seizures: depressed mood, reduced energy, pain, insomnia, anxiety, mood swings, and outbursts of irritability and AB irritability [<xref ref-type="bibr" rid="B117">117</xref>]. Patients with epilepsy may also present atypical behavioral symptoms that occur peri-ictally, i.e., before, during, or after an epileptic seizure [<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B117">117</xref>]. Prodromal and immediate postictal symptoms often manifest with dysphoric, emotional, and behavioral symptoms [<xref ref-type="bibr" rid="B118">118</xref>]. Postictal psychosis is a potentially dangerous complication of chronic epilepsy usually occurring with a lucid interval within one week after a cluster of (usually tonic-clonic) seizures. It may be associated with religious, paranoid, and persecutory ideas causing pronounced aggressive behavior [<xref ref-type="bibr" rid="B119">119</xref>]. A case of homicide was recently reported during postictal psychosis and was thought to be promoted by a preceding treatment switch from carbamazepine to LEV [<xref ref-type="bibr" rid="B120">120</xref>]. Furthermore, psychiatric symptoms that emerge after seizure control may represent an entity on its own, called “alternative psychosis” (see chapter 6.3). The above-mentioned phenomena illustrate how difficult it can be to distinguish between AED-induced PBAR and endogenous as well as seizure-related psychiatric and behavioral symptoms.</p>
</sec>
<sec id="sec5.3">
<title>5.3. Genetic Influence</title>
<p>Since patients with difficult-to-treat epilepsy and a personal or family history of psychiatric disorders have a higher risk of PBAR, the question of a genetic predisposition has been discussed [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B68">68</xref>]. Recently, numerous copy number variations have been uncovered as important risk factors for the development of multiple neuropsychiatric disorders [<xref ref-type="bibr" rid="B121">121</xref>]. Such chromosomal rearrangements may underlie a broad phenotype spectrum, ranging from normal development to mild learning- or intellectual disabilities, epilepsy, and psychiatric diseases, such as autism spectrum disorders and schizophrenia, often in combination [<xref ref-type="bibr" rid="B122">122</xref>–<xref ref-type="bibr" rid="B124">124</xref>]. The epilepsy is frequently of generalized type [<xref ref-type="bibr" rid="B121">121</xref>]. Conceivably, this vulnerable group of patients may harbor a particular susceptibility to develop complex PBAR from AEDs. Moreover, an association study by Helmstaedter et al. investigated LEV as a model AED for PBAR and found several genetic polymorphisms that are associated with reduced dopaminergic activity in patients having the most pronounced reactions [<xref ref-type="bibr" rid="B125">125</xref>]. However, as there are no further such studies, it is not clear whether these findings apply to other AEDs besides LEV [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B125">125</xref>].</p>
</sec>
<sec id="sec5.4">
<title>5.4. Intellectual Disability</title>
<p>From a lifetime perspective, people with intellectual disability are among the most drug-exposed groups in society. Epilepsy is the most common comorbidity in these individuals. They may not be able to report and describe adverse reactions from AEDs in the form of slowing of central information processing (114). Symptoms of overdosing, such as sedation, ataxia, or blurred vision, may even occur unnoticed by the caregivers [<xref ref-type="bibr" rid="B68">68</xref>, <xref ref-type="bibr" rid="B84">84</xref>, <xref ref-type="bibr" rid="B126">126</xref>]. Such unspecific adverse reactions are not uncommon with LEV, PER, and TPM (<xref ref-type="table" rid="tab1">Table 1</xref>) and may be indirectly expressed as disturbed behavior and interpreted as specific pharmacodynamic effects [<xref ref-type="bibr" rid="B57">57</xref>, <xref ref-type="bibr" rid="B127">127</xref>, <xref ref-type="bibr" rid="B128">128</xref>]. It is also well-known that sedating drugs can paradoxically induce hyperactivity, especially in children [<xref ref-type="bibr" rid="B57">57</xref>]. TPM, in addition, can impair language function and reduce verbal fluency [<xref ref-type="bibr" rid="B128">128</xref>, <xref ref-type="bibr" rid="B129">129</xref>]. This may be more pronounced in patients with lower educational levels, suggesting an impact of baseline cerebral performance [<xref ref-type="bibr" rid="B129">129</xref>]. Impaired ability to express oneself may trigger AB. Moreover, these patients often use AED polytherapy and other drugs targeting the brain, which may cause pharmacodynamic interactions and further increase the risk of disturbed behavior [<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B115">115</xref>].</p>
<p>In contrast, the “release phenomenon” denotes challenging conduct in patients disabled by a previously severe drug-resistant seizure disorder who obtain seizure control with newer drugs with less impact on alertness and cognition. This occurs usually in patients with intellectual disability, who may express increased vigilance and self-assertion as AB. A more demanding behavior should not invariably be interpreted as a sign of drug toxicity [114].</p>
</sec>
</sec>
<sec id="sec6">
<title>6. Other Potential Mechanisms</title>
<sec id="sec6.1">
<title>6.1. Hormonal and Biochemical Aspects</title>
<p>Various steroid hormones modulate AB, and studies have shown an association between high CNS levels of testosterone and impulsive-aggressive behavior [<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B130">130</xref>–<xref ref-type="bibr" rid="B132">132</xref>]. Testosterone may interact with the serotonin system and increase neuronal activity in brain regions involved in AB, such as the amygdala, hypothalamus, and periaqueductal gray matter (PAG) [<xref ref-type="bibr" rid="B130">130</xref>, <xref ref-type="bibr" rid="B131">131</xref>]. Low levels of serotonin together with high levels of testosterone seem to play an important role in aggression [<xref ref-type="bibr" rid="B130">130</xref>]. Synthetic testosterone analogues have been shown to alter the expression of GABA<sub>A</sub> and DA receptors and increase levels of vasopressin, substance P, and stress hormones [<xref ref-type="bibr" rid="B133">133</xref>]. Not surprisingly, aggressive behavior is much more frequently seen in male than in female patients with epilepsy [<xref ref-type="bibr" rid="B134">134</xref>, <xref ref-type="bibr" rid="B135">135</xref>]. However, while women show less aggression, they tend to be more irritable than men [<xref ref-type="bibr" rid="B136">136</xref>].</p>
<p>It has been suggested that LEV inhibits aromatase, an enzyme that converts testosterone to estradiol [<xref ref-type="bibr" rid="B137">137</xref>, <xref ref-type="bibr" rid="B138">138</xref>]. This would imply that patients using LEV may have higher levels of testosterone (and, possibly, reduced levels of estradiol). This could, at least partially, explain the increased prevalence of AB in patients using LEV. Birger et al. (2003) demonstrated that administration of testosterone in rats increased the expression of 5-HT<sub>2A</sub> receptors and other 5-HT binding sites and that this most probably was an effect mediated by estradiol [<xref ref-type="bibr" rid="B130">130</xref>]. Inhibition of aromatase by LEV could therefore produce a dual negative effect on the serotonin system: increased testosterone levels may downregulate 5-HT, and decreased estradiol produces fewer 5-HT receptors and binding sites.</p>
<p>Stress is a trigger for both epilepsy and psychiatric disorders, and there is a significant overlap of the neural networks involved in stress and aggression [<xref ref-type="bibr" rid="B139">139</xref>, <xref ref-type="bibr" rid="B140">140</xref>]. It is possible that AEDs directly or indirectly affect those hormones of the hypothalamus-pituitary-adrenal gland axis that are involved in regulation of stress responses [<xref ref-type="bibr" rid="B139">139</xref>].</p>
<p>Brodie et al. [<xref ref-type="bibr" rid="B4">4</xref>] point out that TPM, a carbonic anhydrase inhibitor, can induce metabolic acidosis, which is associated with aggression and irritability [<xref ref-type="bibr" rid="B4">4</xref>]. Interestingly, this pharmacologic characteristic is shared by zonisamide, an AED that is also associated with an elevated risk of PBAR [<xref ref-type="bibr" rid="B18">18</xref>].</p>
</sec>
<sec id="sec6.2">
<title>6.2. Epigenetics</title>
<p>Epigenetics explains how dynamic environmental factors can affect the expression of genes and the pathophysiology of disease states without changing the genetic code [<xref ref-type="bibr" rid="B141">141</xref>]. In recent years, much attention has been directed toward AEDs and their impact on crucial epigenetic processes such as histone acetylation and DNA methylation [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B142">142</xref>]. Histones are proteins that are bound to the DNA. Their acetylation state affects the accessibility of the DNA and, thus, gene transcription and expression [<xref ref-type="bibr" rid="B142">142</xref>]. Acetylation is controlled by two enzymes called histone acetyltransferase (HAT) and histone deacetylase (HDAC). While little is known about the exact mechanisms, an association between HDAC and behavior has been found, including AB [<xref ref-type="bibr" rid="B142">142</xref>].</p>
<p>Valproate, a broad-spectrum AED and a mood stabilizer, possesses several MOAs, including inhibition of HDAC [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B142">142</xref>, <xref ref-type="bibr" rid="B143">143</xref>]. This contributes to increased expression of reelin and GAD67 in cortical GABAergic interneurons which may reduce aggression, as downregulation of reelin and GAD67 has been observed in patients with schizophrenia and bipolar disorder. These patients often show more anger and aggression than the general population [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B142">142</xref>]. It has also been found that TPM and the main metabolite of LEV inhibit HDAC, but for now little is known how that may affect AB [<xref ref-type="bibr" rid="B143">143</xref>].</p>
<p>Further epigenetic mechanisms associated with AEDs and aggression are modulation of the serotonin system in the amygdala and the prefrontal cortex, as well as monoaminoxidase A activity [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B142">142</xref>]. By now, it is not known whether PER exerts epigenetic effects.</p>
</sec>
<sec id="sec6.3">
<title>6.3. Forced Normalization and Alternative Psychosis</title>
<p>“Forced normalization” (FN) is an EEG phenomenon [<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B115">115</xref>] that was first described by Landolt in 1953. He observed that patients with epilepsy developed psychiatric symptoms, mainly psychosis, when their EEG became normal and seizure control was achieved [<xref ref-type="bibr" rid="B144">144</xref>]. In 1965, Tellenbach introduced the term “alternative psychosis” which is the clinical counterpart of FN [<xref ref-type="bibr" rid="B115">115</xref>]. Later, “alternative” phenomena have been expanded to include other psychiatric symptoms as well, e.g., depression, anxiety, hypomania/mania, and aggression [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B115">115</xref>, <xref ref-type="bibr" rid="B145">145</xref>]. Hence, it is possible that the psychiatric adverse reactions seen with AEDs not necessarily are direct pharmacological effects, but sometimes a neurophysiological consequence of improved seizure control.</p>
<p>Although the concept of FN/alternative psychosis was long ago acknowledged, its underlying mechanisms are essentially unknown [<xref ref-type="bibr" rid="B56">56</xref>, <xref ref-type="bibr" rid="B146">146</xref>, <xref ref-type="bibr" rid="B147">147</xref>]. It is thought to be related to the antagonism between epilepsy and psychosis, as epileptic seizures occasionally abort psychiatric symptoms (which also is the rationale for treating psychiatric conditions with electroconvulsive therapy) [<xref ref-type="bibr" rid="B148">148</xref>]. It has been speculated that some patients with epilepsy have a preexisting imbalance of neurotransmitters that would cause psychiatric symptoms would they not be prevented by recurrent epileptic seizures that lead to stabilization. A related possible explanation is the kindling phenomenon, where repeated stimulation of the limbic system, mainly the amygdala, is supposed to induce behavioral changes [<xref ref-type="bibr" rid="B146">146</xref>, <xref ref-type="bibr" rid="B147">147</xref>, <xref ref-type="bibr" rid="B149">149</xref>].</p>
<p>It has been reported that alternative psychosis occurs in relation to the introduction of new AEDs, and both LEV and TPM are examples [<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B146">146</xref>, <xref ref-type="bibr" rid="B149">149</xref>]. It is, however, important to understand that alternative psychiatric symptoms are not limited exclusively to drug treatment as it also may occur when seizure control is achieved by other methods, e.g., surgery [<xref ref-type="bibr" rid="B42">42</xref>, <xref ref-type="bibr" rid="B115">115</xref>, <xref ref-type="bibr" rid="B147">147</xref>]. From this, it follows that this clinical phenomenon does not depend on one distinct pharmacologic mechanism [<xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B67">67</xref>]. Moreover, the concept of FN/alternative psychosis alone does not fully explain AB with AED use, since several studies have shown that PBAR also occurs in patients who do not become seizure-free [<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B32">32</xref>, <xref ref-type="bibr" rid="B67">67</xref>]. Some studies also report that AB may be associated with deteriorated seizure control, which again illustrates the complex relationship between epileptic activity and behavior [<xref ref-type="bibr" rid="B56">56</xref>]. In clinical practice, it is important to clarify if psychiatric symptoms in patients using AEDs are adverse drug reactions, a consequence of seizure control, seizure breakthrough or an expression of a more complex, endogenous aptness for psychiatric disorders [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B67">67</xref>].</p>
</sec>
<sec id="sec6.4">
<title>6.4. Aggression Induced by Other Drugs</title>
<p>To identify possible mechanisms by which AEDs may induce AB, it could be useful to look at other drugs that also have the potential to induce this adverse reaction. Interestingly, several drugs used to treat aggression have been reported to induce AB. Among those are benzodiazepines, antidepressants, central stimulants [<xref ref-type="bibr" rid="B150">150</xref>–<xref ref-type="bibr" rid="B152">152</xref>], and AEDs, among them TPM [<xref ref-type="bibr" rid="B153">153</xref>].</p>
<p>Benzodiazepines increase the inhibitory actions of GABA via allosteric modulation of the GABA<sub>A</sub> receptor, thereby increasing its affinity for GABA [<xref ref-type="bibr" rid="B12">12</xref>, <xref ref-type="bibr" rid="B150">150</xref>]. While most adverse reactions to sedative drugs are predictable, some patients may develop paradoxical reactions such as increased irritability, aggression, hostility, and impulsivity. Usually, this occurs in children, in elderly patients, and in patients with intellectual disability [<xref ref-type="bibr" rid="B150">150</xref>]. The paradoxical reactions are presumably due to disinhibition of behavioral networks that normally are balanced. This is based on the theory that GABA plays a role in AB, yet it is speculative [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B150">150</xref>]. It has been found that the risk of AB is doubled in children and adolescents using antidepressants (SSRI, SNRI) that increase the amount of 5-HT and NA in synaptic clefts [<xref ref-type="bibr" rid="B151">151</xref>]. These monoamines are involved in AB [<xref ref-type="bibr" rid="B4">4</xref>]. Among central stimulants, particularly amphetamine and its derivatives are associated with irritability [<xref ref-type="bibr" rid="B152">152</xref>]. Amphetamines both increase the release and inhibit the reuptake of NE and DA in the synapse. In higher doses, they also inhibit 5-HT. High levels of NA and DA and low levels of 5-HT have been suggested to promote aggression and irritability [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B152">152</xref>].</p>
<p>Other drugs that can induce AB are antihistamines, statins, and anabolic steroids [<xref ref-type="bibr" rid="B154">154</xref>–<xref ref-type="bibr" rid="B156">156</xref>]. In children, second-generation antihistamines can produce aggression, agitation, and hyperactivity [<xref ref-type="bibr" rid="B154">154</xref>]. Antihistamines act primarily as antagonists at the histamine H1 receptor. As mentioned above, low levels of 5-HT may promote AB, and it has been shown that histamine and H1 receptors in the brain can modulate AB via the 5-HT system [<xref ref-type="bibr" rid="B14">14</xref>]. Statins are another class of drugs that may induce increased irritability, which suggests a relationship between lowered cholesterol and AB [<xref ref-type="bibr" rid="B155">155</xref>]. These drugs are commonly used in combination with AEDs in elderly patients with vascular epilepsy.</p>
<p>It is not surprising that AB is a common adverse reaction to anabolic-androgenic steroids (AAS) [<xref ref-type="bibr" rid="B133">133</xref>, <xref ref-type="bibr" rid="B156">156</xref>, <xref ref-type="bibr" rid="B157">157</xref>]. Studies have shown that AAS not only increase AB temporarily, but also may lead to psychiatric long-term consequences as their use in or close to puberty may induce permanent changes in the developing brain [<xref ref-type="bibr" rid="B133">133</xref>, <xref ref-type="bibr" rid="B156">156</xref>, <xref ref-type="bibr" rid="B157">157</xref>]. AAS has been shown to modify the expression of cerebral androgen, GABA<sub>A</sub>, and DA receptors, as well as affect the 5-HT system and the levels of neuroactive substances, e.g., vasopressin, substance P, and stress hormones [<xref ref-type="bibr" rid="B133">133</xref>]. Carrillo et al. found that AAS reinforce glutamatergic connections between the hypothalamus and the stria terminalis. Their study supports that glutamate and vasopressin are involved in AB [<xref ref-type="bibr" rid="B158">158</xref>].</p>
<p>This review of AB induced by drugs that are not AEDs reveals some pharmacological similarities: (1) the modulation of GABAergic neurotransmission, demonstrated for both LEV and TPM and (2) inhibition of glutamatergic neurotransmission, particularly via the AMPA receptor—this has been demonstrated for LEV, PER, and TPM—and (3) modulation of the 5-HT system, which has been shown for LEV. Possible effects of AEDs on androgen and DA receptors as well as on neuroactive substances are poorly studied, but this does not mean that they do not exist. It must also be kept in mind that PER is one of the newest AEDs on the market. Chances are good that it may have pharmacological properties that have not yet been discovered. Likewise, all other drugs discussed here including LEV and TPM may possess unknown MOAs that contribute to their clinical effects.</p>
</sec>
</sec>
<sec id="sec7">
<title>7. Future Perspectives</title>
<p>Since little is certain and much is speculative regarding AB associated with AED treatment of epilepsy, and since it represents a significant clinical problem, further study on this topic is desirable. Studies on the pharmacological MOAs of AEDs and how they are related to AB would be particularly useful. This includes the search for yet unknown MOAs. New technologies like pharmacological magnetic resonance imaging (phMRI) may help to identify the sites of AED action in the brain [<xref ref-type="bibr" rid="B159">159</xref>]. This could be related to what is known about the etiology and the pathophysiology of AB. As LEV, PER, and TPM share an inhibiting effect on glutamatergic transmission via the AMPA receptor, the latter may represent a promising starting point [<xref ref-type="bibr" rid="B18">18</xref>]. Possible AED effects on hormones like testosterone, oxytocin, and stress hormones as well as on neuroactive substances like vasopressin or substance P deserve further research, e.g., by concentration measurement in CSF or brain tissue. The relation between epigenetic factors and AB is another promising area of future research [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B142">142</xref>]. It is also desirable to develop instruments and clinical routines that help clinicians to define whether psychiatric symptoms in the individual patient are an adverse reaction to AEDs, a consequence of achieved seizure control, the seizure disorder itself and its underlying cause, or the manifestation of endogenous psychiatric conditions [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B67">67</xref>]. Moreover, further clinical research attempting to identify vulnerability factors may be helpful in order to minimize the incidence of these drug effects.</p>
</sec>
<sec id="sec8">
<title>8. Summary and Conclusion</title>
<p>LEV, PER, and TPM are associated with a higher risk of AB than other AEDs. They have various pharmacological MOAs, some of which interfere with neurotransmitters involved in AB. However, it is not clear which of them is the main one responsible for the increased prevalence of AB. In this context, it is important to note that the MOAs we know of today do not necessarily represent the complete and final spectrum of pharmacological effects of these drugs. Future research might unveil additional MOAs. There are indications that particularly 5-HT, glutamate, and GABA are involved in aggression, and the AMPA receptor looks like the most promising target. Other mechanisms by which drugs may induce AB include modulation of testosterone levels and of various neuroactive substances. Little is known about the role of epigenetics in aggression, but it has already been shown for some AEDs that they do interact with epigenetic mechanisms such as histone acetylation and DNA methylation.</p>
<p>The biological vulnerability to PBAR from AEDs is multifaceted. A range of mechanisms and clinical predisposing factors may interact, including the phenomenon of alternative psychosis. <xref ref-type="fig" rid="fig1"> Figure 1</xref> illustrates the complex and multifactorial background of AB in people with epilepsy. Drug related, epilepsy-related, and patient-related elements must be carefully evaluated in each case. Challenging behaviors from non-AED-related causes should be excluded. Consideration of the epilepsy type and etiology and the previous personal or familial psychiatric history should receive particular attention. A low total drug burden and a slow dose titration are prerequisites for best possible risk reduction. Remarkably, PBAR may first be recognized clinically several weeks or months after starting the culprit drug. Of utmost importance is information to the patients, relatives, or caregivers about potential PBAR, and the possibility of their delayed onset. Patients starting AED treatment, particularly with LEV, PER, and TPM, need long-term and comprehensive clinical monitoring with awareness of emergent adverse behavior.</p>
</sec>
</body>
<back>
<sec>
<title>Conflicts of Interest</title>
<p>The authors declare that there is no conflict of interest regarding the publication of this paper.</p>
</sec>
<ref-list>
<ref id="B1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ngugi</surname>
<given-names>A. K.</given-names>
</name>
<name>
<surname>Bottomley</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kleinschmidt</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Newton</surname>
<given-names>C. R.</given-names>
</name>
</person-group>
<article-title>Estimation of the burden of active and life-time epilepsy: a meta-analytic approach</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2010</year>
<volume>51</volume>
<issue>5</issue>
<fpage>883</fpage>
<lpage>890</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2009.02481.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-77951590218</pub-id>
<pub-id pub-id-type="pmid">20067507</pub-id>
</element-citation>
</ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirtz</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Thurman</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Gwinn-Hardy</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Mohamed</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chaudhuri</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Zalutsky</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>How common are the “common” neurologic disorders?</article-title>
<source/>
<italic toggle="yes">Neurology</italic>
<year>2007</year>
<volume>68</volume>
<issue>5</issue>
<fpage>326</fpage>
<lpage>337</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000252807.38124.a3</pub-id>
<pub-id pub-id-type="other">2-s2.0-33846604242</pub-id>
<pub-id pub-id-type="pmid">17261678</pub-id>
</element-citation>
</ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brodie</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Bamagous</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kwan</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Improved outcomes in newly diagnosed epilepsy</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2009</year>
<volume>50</volume>
<issue>11</issue>
<fpage>411</fpage>
<lpage>412</lpage>
</element-citation>
</ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brodie</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Besag</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ettinger</surname>
<given-names>A. B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Epilepsy, antiepileptic drugs, and aggression: an evidence-based review</article-title>
<source/>
<italic toggle="yes">Pharmacological Reviews</italic>
<year>2016</year>
<volume>68</volume>
<issue>3</issue>
<fpage>563</fpage>
<lpage>602</lpage>
<pub-id pub-id-type="doi">10.1124/pr.115.012021</pub-id>
<pub-id pub-id-type="other">2-s2.0-84968547876</pub-id>
<pub-id pub-id-type="pmid">27255267</pub-id>
</element-citation>
</ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Andres</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kerling</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hamer</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Winterholler</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Behavioural changes in patients with intellectual disability treated with brivaracetam</article-title>
<source/>
<italic toggle="yes">Acta Neurologica Scandinavica</italic>
<year>2018</year>
<volume>138</volume>
<issue>3</issue>
<fpage>195</fpage>
<lpage>202</lpage>
<pub-id pub-id-type="doi">10.1111/ane.12943</pub-id>
<pub-id pub-id-type="other">2-s2.0-85045700146</pub-id>
<pub-id pub-id-type="pmid">29658982</pub-id>
</element-citation>
</ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinig</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>von Podewils</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Moddel</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2017</year>
<volume>58</volume>
<issue>7</issue>
<fpage>1208</fpage>
<lpage>1216</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13768</pub-id>
<pub-id pub-id-type="other">2-s2.0-85018424666</pub-id>
<pub-id pub-id-type="pmid">28480518</pub-id>
</element-citation>
</ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Mula</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hermann</surname>
<given-names>B. P.</given-names>
</name>
</person-group>
<article-title>Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan</article-title>
<source/>
<italic toggle="yes">The Lancet</italic>
<year>2012</year>
<volume>380</volume>
<issue>9848</issue>
<fpage>1180</fpage>
<lpage>1192</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(12)61455-X</pub-id>
<pub-id pub-id-type="other">2-s2.0-84866719258</pub-id>
</element-citation>
</ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alper</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Barry</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Balabanov</surname>
<given-names>A. J.</given-names>
</name>
</person-group>
<article-title>Treatment of psychosis, aggression, and irritability in patients with epilepsy</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2002</year>
<volume>3</volume>
<issue>5</issue>
<fpage>13</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1016/S1525-5069(02)00500-5</pub-id>
<pub-id pub-id-type="pmid">12609315</pub-id>
</element-citation>
</ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calles</surname>
<given-names>J. L.</given-names>
<suffix>Jr.</suffix>
</name>
</person-group>
<article-title>Aggressive behaviors</article-title>
<source/>
<italic toggle="yes">Journal of Alternative Medicine Research</italic>
<year>2016</year>
<volume>8</volume>
<issue>4</issue>
<fpage>379</fpage>
<lpage>392</lpage>
</element-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crocker</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Mercier</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lachapelle</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Brunet</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Morin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>M. E.</given-names>
</name>
</person-group>
<article-title>Prevalence and types of aggressive behaviour among adults with intellectual disabilities</article-title>
<source/>
<italic toggle="yes">Journal of Intellectual Disability Research</italic>
<year>2006</year>
<volume>50</volume>
<issue>9</issue>
<fpage>652</fpage>
<lpage>661</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2788.2006.00815.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-33746467494</pub-id>
<pub-id pub-id-type="pmid">16901292</pub-id>
</element-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munshi</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Oken</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Guild</surname>
<given-names>D. J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The use of antiepileptic drugs (AEDs) for the treatment of pediatric aggression and mood disorders</article-title>
<source/>
<italic toggle="yes">Pharmaceuticals</italic>
<year>2010</year>
<volume>3</volume>
<issue>9</issue>
<fpage>2986</fpage>
<lpage>3004</lpage>
<pub-id pub-id-type="doi">10.3390/ph3092986</pub-id>
<pub-id pub-id-type="other">2-s2.0-77957281883</pub-id>
<pub-id pub-id-type="pmid">27713387</pub-id>
</element-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Comai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tau</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gobbi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>The psychopharmacology of aggressive behavior: a translational approach: part 1: neurobiology</article-title>
<source/>
<italic toggle="yes">Journal of Clinical Psychopharmacology</italic>
<year>2012</year>
<volume>32</volume>
<issue>1</issue>
<fpage>83</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1097/JCP.0b013e31823f8770</pub-id>
<pub-id pub-id-type="other">2-s2.0-84855346059</pub-id>
<pub-id pub-id-type="pmid">22198449</pub-id>
</element-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Comai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tau</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Pavlovic</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Gobbi</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>The psychopharmacology of aggressive behavior: a translational approach</article-title>
<source/>
<italic toggle="yes">Journal of Clinical Psychopharmacology</italic>
<year>2012</year>
<volume>32</volume>
<issue>2</issue>
<fpage>237</fpage>
<lpage>260</lpage>
<pub-id pub-id-type="doi">10.1097/JCP.0b013e31824929d6</pub-id>
<pub-id pub-id-type="other">2-s2.0-84855345321</pub-id>
<pub-id pub-id-type="pmid">22367663</pub-id>
</element-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nelson</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Chiavegatto</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Molecular basis of aggression</article-title>
<source/>
<italic toggle="yes">Trends in Neurosciences</italic>
<year>2001</year>
<volume>24</volume>
<issue>12</issue>
<fpage>713</fpage>
<lpage>719</lpage>
<pub-id pub-id-type="doi">10.1016/S0166-2236(00)01996-2</pub-id>
<pub-id pub-id-type="other">2-s2.0-0035576877</pub-id>
<pub-id pub-id-type="pmid">11718876</pub-id>
</element-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giussani</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Canelli</surname>
<given-names>V.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antiepileptic drug discontinuation by people with epilepsy in the general population</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2017</year>
<volume>58</volume>
<issue>9</issue>
<fpage>1524</fpage>
<lpage>1532</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13853</pub-id>
<pub-id pub-id-type="other">2-s2.0-85028746720</pub-id>
<pub-id pub-id-type="pmid">28744867</pub-id>
</element-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marson</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Al-Kharusi</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Alwaidh</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial</article-title>
<source/>
<italic toggle="yes">The Lancet</italic>
<year>2007</year>
<volume>369</volume>
<issue>9566</issue>
<fpage>1000</fpage>
<lpage>1015</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(07)60460-7</pub-id>
<pub-id pub-id-type="other">2-s2.0-33947241772</pub-id>
<pub-id pub-id-type="pmid">17382827</pub-id>
</element-citation>
</ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perucca</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gilliam</surname>
<given-names>F. G.</given-names>
</name>
</person-group>
<article-title>Adverse effects of antiepileptic drugs</article-title>
<source/>
<italic toggle="yes">Lancet Neurology</italic>
<year>2012</year>
<volume>11</volume>
<issue>9</issue>
<fpage>792</fpage>
<lpage>802</lpage>
<pub-id pub-id-type="doi">10.1016/S1474-4422(12)70153-9</pub-id>
<pub-id pub-id-type="other">2-s2.0-84865115095</pub-id>
<pub-id pub-id-type="pmid">22832500</pub-id>
</element-citation>
</ref>
<ref id="B18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hirsch</surname>
<given-names>L. J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2017</year>
<volume>76</volume>
<fpage>24</fpage>
<lpage>31</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2017.08.039</pub-id>
<pub-id pub-id-type="other">2-s2.0-85029514008</pub-id>
<pub-id pub-id-type="pmid">28931473</pub-id>
</element-citation>
</ref>
<ref id="B19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Detyniecki</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psychiatric and behavioral side effects of anti-epileptic drugs in adolescents and children with epilepsy</article-title>
<source/>
<italic toggle="yes">European Journal of Paediatric Neurology</italic>
<year>2017</year>
<volume>21</volume>
<issue>3</issue>
<fpage>441</fpage>
<lpage>449</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejpn.2017.02.003</pub-id>
<pub-id pub-id-type="other">2-s2.0-85013443487</pub-id>
<pub-id pub-id-type="pmid">28238621</pub-id>
</element-citation>
</ref>
<ref id="B20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Besag</surname>
<given-names>F. M. C.</given-names>
</name>
</person-group>
<article-title>Risk factors for psychiatric and behavioural adverse events associated with antiepileptic drugs in adolescents and children</article-title>
<source/>
<italic toggle="yes">European Journal of Paediatric Neurology</italic>
<year>2017</year>
<volume>21</volume>
<issue>3</issue>
<fpage>423</fpage>
<lpage>424</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejpn.2017.03.008</pub-id>
<pub-id pub-id-type="other">2-s2.0-85017605032</pub-id>
<pub-id pub-id-type="pmid">28433232</pub-id>
</element-citation>
</ref>
<ref id="B21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stephen</surname>
<given-names>L. J.</given-names>
</name>
<name>
<surname>Wishart</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brodie</surname>
<given-names>M. J.</given-names>
</name>
</person-group>
<article-title>Psychiatric side effects and antiepileptic drugs: observations from prospective audits</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2017</year>
<volume>71, Part A</volume>
<fpage>73</fpage>
<lpage>78</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2017.04.003</pub-id>
<pub-id pub-id-type="other">2-s2.0-85019638266</pub-id>
<pub-id pub-id-type="pmid">28551500</pub-id>
</element-citation>
</ref>
<ref id="B22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ortega</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Abraira</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Marti</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Anger assessment in patients treated with brivaracetam</article-title>
<source/>
<italic toggle="yes">Clinical Neuropharmacology</italic>
<year>2018</year>
<volume>41</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1097/WNF.0000000000000258</pub-id>
<pub-id pub-id-type="other">2-s2.0-85041171694</pub-id>
<pub-id pub-id-type="pmid">29300204</pub-id>
</element-citation>
</ref>
<ref id="B23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toledo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Whitesides</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schiemann</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2016</year>
<volume>57</volume>
<issue>7</issue>
<fpage>1139</fpage>
<lpage>1151</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13416</pub-id>
<pub-id pub-id-type="other">2-s2.0-84977510958</pub-id>
<pub-id pub-id-type="pmid">27265725</pub-id>
</element-citation>
</ref>
<ref id="B24">
<label>24</label>
<element-citation publication-type="other">
<collab>Keppra European SPC</collab>
<article-title>EMA</article-title>
<comment>September 2017, <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/no_NO/document_library/EPAR_-_Product_Information/human/000277/WC500041334.pdf">http://www.ema.europa.eu/docs/no_NO/document_library/EPAR_-_Product_Information/human/000277/WC500041334.pdf</ext-link></comment>
</element-citation>
</ref>
<ref id="B25">
<label>25</label>
<element-citation publication-type="other">
<collab>Fycompa European SPC</collab>
<article-title>EMA</article-title>
<comment>September 2017, <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/no_NO/document_library/EPAR_-_Product_Information/human/002434/WC500130815.pdf">http://www.ema.europa.eu/docs/no_NO/document_library/EPAR_-_Product_Information/human/002434/WC500130815.pdf</ext-link></comment>
</element-citation>
</ref>
<ref id="B26">
<label>26</label>
<element-citation publication-type="other">
<collab>Topamax European SPC</collab>
<article-title>EMA</article-title>
<comment>September 2017, <ext-link ext-link-type="uri" xlink:href="https://www.legemiddelsok.no/_layouts/15/Preparatomtaler/Spc/1995-00790.pdf">https://www.legemiddelsok.no/_layouts/15/Preparatomtaler/Spc/1995-00790.pdf</ext-link></comment>
</element-citation>
</ref>
<ref id="B27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weintraub</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Buchsbaum</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Resor</surname>
<given-names>S. R.</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Hirsch</surname>
<given-names>L. J.</given-names>
</name>
</person-group>
<article-title>Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2007</year>
<volume>10</volume>
<issue>1</issue>
<fpage>105</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2006.08.008</pub-id>
<pub-id pub-id-type="other">2-s2.0-33846357448</pub-id>
<pub-id pub-id-type="pmid">17079191</pub-id>
</element-citation>
</ref>
<ref id="B28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eddy</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Rickards</surname>
<given-names>H. E.</given-names>
</name>
<name>
<surname>Cavanna</surname>
<given-names>A. E.</given-names>
</name>
</person-group>
<article-title>Behavioral adverse effects of antiepileptic drugs in epilepsy</article-title>
<source/>
<italic toggle="yes">Journal of Clinical Psychopharmacology</italic>
<year>2012</year>
<volume>32</volume>
<issue>3</issue>
<fpage>362</fpage>
<lpage>375</lpage>
<pub-id pub-id-type="doi">10.1097/JCP.0b013e318253a186</pub-id>
<pub-id pub-id-type="other">2-s2.0-84861017730</pub-id>
<pub-id pub-id-type="pmid">22544012</pub-id>
</element-citation>
</ref>
<ref id="B29">
<label>29</label>
<element-citation publication-type="other">
<collab>Briviact European SPC</collab>
<article-title>EMA</article-title>
<comment>
<ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003898/WC500200206.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003898/WC500200206.pdf</ext-link>
</comment>
</element-citation>
</ref>
<ref id="B30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinkelacker</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Dietl</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Widman</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lengler</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Elger</surname>
<given-names>C. E.</given-names>
</name>
</person-group>
<article-title>Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2003</year>
<volume>4</volume>
<issue>5</issue>
<fpage>537</fpage>
<lpage>547</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2003.07.008</pub-id>
<pub-id pub-id-type="other">2-s2.0-0242522159</pub-id>
<pub-id pub-id-type="pmid">14527496</pub-id>
</element-citation>
</ref>
<ref id="B31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mula</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trimble</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>J. W.</given-names>
</name>
</person-group>
<article-title>Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam</article-title>
<source/>
<italic toggle="yes">Seizure</italic>
<year>2004</year>
<volume>13</volume>
<issue>1</issue>
<fpage>55</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="doi">10.1016/S1059-1311(03)00111-0</pub-id>
<pub-id pub-id-type="other">2-s2.0-0942287940</pub-id>
<pub-id pub-id-type="pmid">14741183</pub-id>
</element-citation>
</ref>
<ref id="B32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cramer</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>De Rue</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Devinsky</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Edrich</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Trimble</surname>
<given-names>M. R.</given-names>
</name>
</person-group>
<article-title>A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2003</year>
<volume>4</volume>
<issue>2</issue>
<fpage>124</fpage>
<lpage>132</lpage>
<pub-id pub-id-type="doi">10.1016/s1525-5050(03)00005-2</pub-id>
<pub-id pub-id-type="other">2-s2.0-0038644777</pub-id>
<pub-id pub-id-type="pmid">12697136</pub-id>
</element-citation>
</ref>
<ref id="B33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>H. S.</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H. W.</given-names>
</name>
<name>
<surname>Suh</surname>
<given-names>C. K.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>S. P.</given-names>
</name>
</person-group>
<article-title>Psychiatric symptoms and quality of life in patients with drug-refractory epilepsy receiving adjunctive levetiracetam therapy</article-title>
<source/>
<italic toggle="yes">Journal of Clinical Neurology</italic>
<year>2011</year>
<volume>7</volume>
<issue>3</issue>
<fpage>128</fpage>
<lpage>136</lpage>
<pub-id pub-id-type="doi">10.3988/jcn.2011.7.3.128</pub-id>
<pub-id pub-id-type="other">2-s2.0-80053448898</pub-id>
<pub-id pub-id-type="pmid">22087206</pub-id>
</element-citation>
</ref>
<ref id="B34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ettinger</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>LoPresti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2015</year>
<volume>56</volume>
<issue>8</issue>
<fpage>1252</fpage>
<lpage>1263</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13054</pub-id>
<pub-id pub-id-type="other">2-s2.0-84938738470</pub-id>
<pub-id pub-id-type="pmid">26140524</pub-id>
</element-citation>
</ref>
<ref id="B35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Biro</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Stephani</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Tarallo</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies: first experiences</article-title>
<source/>
<italic toggle="yes">Neuropediatrics</italic>
<year>2015</year>
<volume>46</volume>
<issue>2</issue>
<fpage>110</fpage>
<lpage>115</lpage>
<pub-id pub-id-type="doi">10.1055/s-0035-1546276</pub-id>
<pub-id pub-id-type="other">2-s2.0-84939946714</pub-id>
<pub-id pub-id-type="pmid">25730374</pub-id>
</element-citation>
</ref>
<ref id="B36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Snoeijen-Schouwenaars</surname>
<given-names>F. M.</given-names>
</name>
<name>
<surname>van Ool</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>I. Y.</given-names>
</name>
<name>
<surname>Schelhaas</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Majoie</surname>
<given-names>M. H.</given-names>
</name>
</person-group>
<article-title>Evaluation of perampanel in patients with intellectual disability and epilepsy</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2017</year>
<volume>66</volume>
<fpage>64</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2016.10.013</pub-id>
<pub-id pub-id-type="other">2-s2.0-85007154023</pub-id>
<pub-id pub-id-type="pmid">28038388</pub-id>
</element-citation>
</ref>
<ref id="B37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huber</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Schmid</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>A two-year retrospective evaluation of perampanel in patients with highly drug-resistant epilepsy and cognitive impairment</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2017</year>
<volume>66</volume>
<fpage>74</fpage>
<lpage>79</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2016.10.020</pub-id>
<pub-id pub-id-type="other">2-s2.0-85007165348</pub-id>
<pub-id pub-id-type="pmid">28038390</pub-id>
</element-citation>
</ref>
<ref id="B38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mula</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trimble</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Lhatoo</surname>
<given-names>S. D.</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>J. W.</given-names>
</name>
</person-group>
<article-title>Topiramate and psychiatric adverse events in patients with epilepsy</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2003</year>
<volume>44</volume>
<issue>5</issue>
<fpage>659</fpage>
<lpage>663</lpage>
<pub-id pub-id-type="doi">10.1046/j.1528-1157.2003.05402.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-0037989698</pub-id>
<pub-id pub-id-type="pmid">12752464</pub-id>
</element-citation>
</ref>
<ref id="B39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Labiner</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Ettinger</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Fakhoury</surname>
<given-names>T. A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2009</year>
<volume>50</volume>
<issue>3</issue>
<fpage>434</fpage>
<lpage>442</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2008.01792.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-61849184228</pub-id>
<pub-id pub-id-type="pmid">19016830</pub-id>
</element-citation>
</ref>
<ref id="B40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moavero</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Santarone</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Galasso</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Curatolo</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Cognitive and behavioral effects of new antiepileptic drugs in pediatric epilepsy</article-title>
<source/>
<italic toggle="yes">Brain &amp; Development</italic>
<year>2017</year>
<volume>39</volume>
<issue>6</issue>
<fpage>464</fpage>
<lpage>469</lpage>
<pub-id pub-id-type="doi">10.1016/j.braindev.2017.01.006</pub-id>
<pub-id pub-id-type="other">2-s2.0-85012027106</pub-id>
<pub-id pub-id-type="pmid">28202262</pub-id>
</element-citation>
</ref>
<ref id="B41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nadkarni</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Devinsky</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Psychotropic effects of antiepileptic drugs</article-title>
<source/>
<italic toggle="yes">Epilepsy Currents</italic>
<year>2005</year>
<volume>5</volume>
<issue>5</issue>
<fpage>176</fpage>
<lpage>181</lpage>
<pub-id pub-id-type="doi">10.1111/j.1535-7511.2005.00056.x</pub-id>
<pub-id pub-id-type="pmid">16175217</pub-id>
</element-citation>
</ref>
<ref id="B42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmitz</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Effects of antiepileptic drugs on mood and behavior</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2006</year>
<volume>47</volume>
<issue>s2</issue>
<fpage>28</fpage>
<lpage>33</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2006.00684.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-33750583237</pub-id>
<pub-id pub-id-type="pmid">17105456</pub-id>
</element-citation>
</ref>
<ref id="B43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Dobrinsky</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Patten</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Laurenza</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Perampanel with concomitant levetiracetam and topiramate: post hoc analysis of adverse events related to hostility and aggression</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2017</year>
<volume>75</volume>
<fpage>79</fpage>
<lpage>85</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2017.06.038</pub-id>
<pub-id pub-id-type="other">2-s2.0-85027687633</pub-id>
<pub-id pub-id-type="pmid">28830031</pub-id>
</element-citation>
</ref>
<ref id="B44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Liso</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Vigevano</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Specchio</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies—an Italian observational multicenter study</article-title>
<source/>
<italic toggle="yes">Epilepsy Research</italic>
<year>2016</year>
<volume>127</volume>
<fpage>93</fpage>
<lpage>100</lpage>
<pub-id pub-id-type="doi">10.1016/j.eplepsyres.2016.08.021</pub-id>
<pub-id pub-id-type="other">2-s2.0-84989913568</pub-id>
<pub-id pub-id-type="pmid">27568598</pub-id>
</element-citation>
</ref>
<ref id="B45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosenfeld</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Conry</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lagae</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study</article-title>
<source/>
<italic toggle="yes">European Journal of Paediatric Neurology</italic>
<year>2015</year>
<volume>19</volume>
<issue>4</issue>
<fpage>435</fpage>
<lpage>445</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejpn.2015.02.008</pub-id>
<pub-id pub-id-type="other">2-s2.0-84931561860</pub-id>
<pub-id pub-id-type="pmid">25823975</pub-id>
</element-citation>
</ref>
<ref id="B46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rugg-Gunn</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Adverse effects and safety profile of perampanel: a review of pooled data</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2014</year>
<volume>55</volume>
<issue>s1</issue>
<fpage>13</fpage>
<lpage>15</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12504</pub-id>
<pub-id pub-id-type="other">2-s2.0-84895773921</pub-id>
<pub-id pub-id-type="pmid">24400692</pub-id>
</element-citation>
</ref>
<ref id="B47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinhoff</surname>
<given-names>B. J.</given-names>
</name>
<name>
<surname>Ben-Menachem</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ryvlin</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2013</year>
<volume>54</volume>
<issue>8</issue>
<fpage>1481</fpage>
<lpage>1489</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12212</pub-id>
<pub-id pub-id-type="other">2-s2.0-84881128534</pub-id>
<pub-id pub-id-type="pmid">23663001</pub-id>
</element-citation>
</ref>
<ref id="B48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zaccara</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Giovannelli</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Cincotta</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Verrotti</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Grillo</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>The adverse event profile of perampanel: meta-analysis of randomized controlled trials</article-title>
<source/>
<italic toggle="yes">European Journal of Neurology</italic>
<year>2013</year>
<volume>20</volume>
<issue>8</issue>
<fpage>1204</fpage>
<lpage>1211</lpage>
<pub-id pub-id-type="doi">10.1111/ene.12170</pub-id>
<pub-id pub-id-type="other">2-s2.0-84880134896</pub-id>
<pub-id pub-id-type="pmid">23607817</pub-id>
</element-citation>
</ref>
<ref id="B49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tekgul</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gencpinar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cavusoglu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dundar</surname>
<given-names>N. O.</given-names>
</name>
</person-group>
<article-title>The efficacy, tolerability and safety of levetiracetam therapy in a pediatric population</article-title>
<source/>
<italic toggle="yes">Seizure</italic>
<year>2016</year>
<volume>36</volume>
<fpage>16</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2016.01.017</pub-id>
<pub-id pub-id-type="other">2-s2.0-84962013924</pub-id>
<pub-id pub-id-type="pmid">26874856</pub-id>
</element-citation>
</ref>
<ref id="B50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chung</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Hank</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Comparative retention rates and long-term tolerability of new antiepileptic drugs</article-title>
<source/>
<italic toggle="yes">Seizure</italic>
<year>2007</year>
<volume>16</volume>
<issue>4</issue>
<fpage>296</fpage>
<lpage>304</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2007.01.004</pub-id>
<pub-id pub-id-type="other">2-s2.0-34247266513</pub-id>
<pub-id pub-id-type="pmid">17267243</pub-id>
</element-citation>
</ref>
<ref id="B51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>B. S.</given-names>
</name>
<name>
<surname>Moon</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y. S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The long-term efficacy and safety of levetiracetam in a tertiary epilepsy centre</article-title>
<source/>
<italic toggle="yes">Epileptic Disorders</italic>
<year>2013</year>
<volume>15</volume>
<issue>3</issue>
<fpage>302</fpage>
<lpage>310</lpage>
<pub-id pub-id-type="doi">10.1684/epd.2013.0599</pub-id>
<pub-id pub-id-type="other">2-s2.0-84884694819</pub-id>
<pub-id pub-id-type="pmid">23981665</pub-id>
</element-citation>
</ref>
<ref id="B52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mula</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trimble</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Yuen</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>J. W.</given-names>
</name>
</person-group>
<article-title>Psychiatric adverse events during levetiracetam therapy</article-title>
<source/>
<italic toggle="yes">Neurology</italic>
<year>2003</year>
<volume>61</volume>
<issue>5</issue>
<fpage>704</fpage>
<lpage>706</lpage>
<pub-id pub-id-type="doi">10.1212/01.WNL.0000078031.32904.0D</pub-id>
<pub-id pub-id-type="other">2-s2.0-0042836602</pub-id>
<pub-id pub-id-type="pmid">12963770</pub-id>
</element-citation>
</ref>
<ref id="B53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>White</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Walczak</surname>
<given-names>T. S.</given-names>
</name>
<name>
<surname>Leppik</surname>
<given-names>I. E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Discontinuation of levetiracetam because of behavioral side effects: a case-control study</article-title>
<source/>
<italic toggle="yes">Neurology</italic>
<year>2003</year>
<volume>61</volume>
<issue>9</issue>
<fpage>1218</fpage>
<lpage>1221</lpage>
<pub-id pub-id-type="doi">10.1212/01.wnl.0000091865.46063.67</pub-id>
<pub-id pub-id-type="other">2-s2.0-0242578835</pub-id>
<pub-id pub-id-type="pmid">14610123</pub-id>
</element-citation>
</ref>
<ref id="B54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Endoh</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shibata</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yoshinaga</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ohtsuka</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Efficacy of topiramate for intractable childhood generalized epilepsy with epileptic spasms: with special reference to electroencephalographic changes</article-title>
<source/>
<italic toggle="yes">Seizure</italic>
<year>2012</year>
<volume>21</volume>
<issue>7</issue>
<fpage>522</fpage>
<lpage>528</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2012.05.009</pub-id>
<pub-id pub-id-type="other">2-s2.0-84863987601</pub-id>
<pub-id pub-id-type="pmid">22698380</pub-id>
</element-citation>
</ref>
<ref id="B55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>E. H.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Short term outcomes of topiramate monotherapy as a first-line treatment in newly diagnosed West syndrome</article-title>
<source/>
<italic toggle="yes">Korean Journal of Pediatrics</italic>
<year>2011</year>
<volume>54</volume>
<issue>9</issue>
<fpage>380</fpage>
<lpage>384</lpage>
<pub-id pub-id-type="doi">10.3345/kjp.2011.54.9.380</pub-id>
<pub-id pub-id-type="other">2-s2.0-84863040275</pub-id>
<pub-id pub-id-type="pmid">22232631</pub-id>
</element-citation>
</ref>
<ref id="B56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mula</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trimble</surname>
<given-names>M. R.</given-names>
</name>
</person-group>
<article-title>The importance of being seizure free: topiramate and psychopathology in epilepsy</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2003</year>
<volume>4</volume>
<issue>4</issue>
<fpage>430</fpage>
<lpage>434</lpage>
<pub-id pub-id-type="doi">10.1016/S1525-5050(03)00145-8</pub-id>
<pub-id pub-id-type="other">2-s2.0-0041919446</pub-id>
<pub-id pub-id-type="pmid">12899865</pub-id>
</element-citation>
</ref>
<ref id="B57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brodtkorb</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Klees</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Nakken</surname>
<given-names>K. O.</given-names>
</name>
<name>
<surname>Lossius</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Johannessen</surname>
<given-names>S. I.</given-names>
</name>
</person-group>
<article-title>Levetiracetam in adult patients with and without learning disability: focus on behavioral adverse effects</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2004</year>
<volume>5</volume>
<issue>2</issue>
<fpage>231</fpage>
<lpage>235</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2003.12.005</pub-id>
<pub-id pub-id-type="other">2-s2.0-1842788117</pub-id>
<pub-id pub-id-type="pmid">15123025</pub-id>
</element-citation>
</ref>
<ref id="B58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ciesielski</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Samson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Steinhoff</surname>
<given-names>B. J.</given-names>
</name>
</person-group>
<article-title>Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term study</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2006</year>
<volume>9</volume>
<issue>3</issue>
<fpage>424</fpage>
<lpage>431</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2006.07.011</pub-id>
<pub-id pub-id-type="other">2-s2.0-33750341158</pub-id>
<pub-id pub-id-type="pmid">16949344</pub-id>
</element-citation>
</ref>
<ref id="B59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de la Loge</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hunter</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Schiemann</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Assessment of behavioral and emotional functioning using standardized instruments in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2010</year>
<volume>18</volume>
<issue>3</issue>
<fpage>291</fpage>
<lpage>298</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2010.04.017</pub-id>
<pub-id pub-id-type="other">2-s2.0-77954383071</pub-id>
<pub-id pub-id-type="pmid">20547106</pub-id>
</element-citation>
</ref>
<ref id="B60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>French</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Edrich</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cramer</surname>
<given-names>J. A.</given-names>
</name>
</person-group>
<article-title>A systematic review of the safety profile of levetiracetam: a new antiepileptic drug</article-title>
<source/>
<italic toggle="yes">Epilepsy Research</italic>
<year>2001</year>
<volume>47</volume>
<issue>1-2</issue>
<fpage>77</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1016/S0920-1211(01)00296-0</pub-id>
<pub-id pub-id-type="other">2-s2.0-0034768383</pub-id>
<pub-id pub-id-type="pmid">11673023</pub-id>
</element-citation>
</ref>
<ref id="B61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guilfoyle</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Follansbee-Junger</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>A. W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antiepileptic drug behavioral side effects and baseline hyperactivity in children and adolescents with new onset epilepsy</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2017</year>
<volume>59</volume>
<issue>1</issue>
<fpage>146</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13946</pub-id>
<pub-id pub-id-type="other">2-s2.0-85033229348</pub-id>
<pub-id pub-id-type="pmid">29114859</pub-id>
</element-citation>
</ref>
<ref id="B62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halma</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>de Louw</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Klinkenberg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Aldenkamp</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>DM</surname>
<given-names>I. J.</given-names>
</name>
<name>
<surname>Majoie</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Behavioral side-effects of levetiracetam in children with epilepsy: a systematic review</article-title>
<source/>
<italic toggle="yes">Seizure</italic>
<year>2014</year>
<volume>23</volume>
<issue>9</issue>
<fpage>685</fpage>
<lpage>691</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2014.06.004</pub-id>
<pub-id pub-id-type="other">2-s2.0-84907706630</pub-id>
<pub-id pub-id-type="pmid">24981629</pub-id>
</element-citation>
</ref>
<ref id="B63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Helmstaedter</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fritz</surname>
<given-names>N. E.</given-names>
</name>
<name>
<surname>Kockelmann</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Kosanetzky</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Elger</surname>
<given-names>C. E.</given-names>
</name>
</person-group>
<article-title>Positive and negative psychotropic effects of levetiracetam</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2008</year>
<volume>13</volume>
<issue>3</issue>
<fpage>535</fpage>
<lpage>541</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2008.05.012</pub-id>
<pub-id pub-id-type="other">2-s2.0-50849129140</pub-id>
<pub-id pub-id-type="pmid">18583196</pub-id>
</element-citation>
</ref>
<ref id="B64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanemura</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Sano</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ohyama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sugita</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Aihara</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Effect of levetiracetam on behavioral problems in pervasive developmental disorder children with epilepsy</article-title>
<source/>
<italic toggle="yes">European Journal of Paediatric Neurology</italic>
<year>2014</year>
<volume>18</volume>
<issue>4</issue>
<fpage>482</fpage>
<lpage>488</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejpn.2014.03.007</pub-id>
<pub-id pub-id-type="other">2-s2.0-84903122722</pub-id>
<pub-id pub-id-type="pmid">24703761</pub-id>
</element-citation>
</ref>
<ref id="B65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kowski</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Weissinger</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gaus</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Fidzinski</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Losch</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Holtkamp</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Specific adverse effects of antiepileptic drugs — a true-to-life monotherapy study</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2016</year>
<volume>54</volume>
<fpage>150</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2015.11.009</pub-id>
<pub-id pub-id-type="other">2-s2.0-84949786414</pub-id>
<pub-id pub-id-type="pmid">26709103</pub-id>
</element-citation>
</ref>
<ref id="B66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mbizvo</surname>
<given-names>G. K.</given-names>
</name>
<name>
<surname>Dixon</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hutton</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Marson</surname>
<given-names>A. G.</given-names>
</name>
</person-group>
<article-title>The adverse effects profile of levetiracetam in epilepsy: a more detailed look</article-title>
<source/>
<italic toggle="yes">International Journal of Neuroscience</italic>
<year>2014</year>
<volume>124</volume>
<issue>9</issue>
<fpage>627</fpage>
<lpage>634</lpage>
<pub-id pub-id-type="doi">10.3109/00207454.2013.866951</pub-id>
<pub-id pub-id-type="other">2-s2.0-84905963170</pub-id>
<pub-id pub-id-type="pmid">24256446</pub-id>
</element-citation>
</ref>
<ref id="B67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mula</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Trimble</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Sander</surname>
<given-names>J. W.</given-names>
</name>
</person-group>
<article-title>Are psychiatric adverse events of antiepileptic drugs a unique entity? A study on topiramate and levetiracetam</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2007</year>
<volume>48</volume>
<issue>12</issue>
<fpage>2322</fpage>
<lpage>2326</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2007.01262.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-36949008112</pub-id>
<pub-id pub-id-type="pmid">17711462</pub-id>
</element-citation>
</ref>
<ref id="B68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mula</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Agrawal</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Mustafa</surname>
<given-names>Z.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Self-reported aggressiveness during treatment with levetiracetam correlates with depression</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2015</year>
<volume>45</volume>
<fpage>64</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2015.03.018</pub-id>
<pub-id pub-id-type="other">2-s2.0-84926227026</pub-id>
<pub-id pub-id-type="pmid">25845494</pub-id>
</element-citation>
</ref>
<ref id="B69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schiemann-Delgado</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Loge Cde</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A long-term open-label extension study assessing cognition and behavior, tolerability, safety, and efficacy of adjunctive levetiracetam in children aged 4 to 16 years with partial-onset seizures</article-title>
<source/>
<italic toggle="yes">Journal of Child Neurology</italic>
<year>2012</year>
<volume>27</volume>
<issue>1</issue>
<fpage>80</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="doi">10.1177/0883073811417183</pub-id>
<pub-id pub-id-type="other">2-s2.0-84863022652</pub-id>
<pub-id pub-id-type="pmid">21876066</pub-id>
</element-citation>
</ref>
<ref id="B70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schoenberg</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Rum</surname>
<given-names>R. S.</given-names>
</name>
<name>
<surname>Osborn</surname>
<given-names>K. E.</given-names>
</name>
<name>
<surname>Werz</surname>
<given-names>M. A.</given-names>
</name>
</person-group>
<article-title>A randomized, double-blind, placebo-controlled crossover study of the effects of levetiracetam on cognition, mood, and balance in healthy older adults</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2017</year>
<volume>58</volume>
<issue>9</issue>
<fpage>1566</fpage>
<lpage>1574</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13849</pub-id>
<pub-id pub-id-type="other">2-s2.0-85028751640</pub-id>
<pub-id pub-id-type="pmid">28731266</pub-id>
</element-citation>
</ref>
<ref id="B71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shukla</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Agarwal</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Poornima</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Behavioral effects and somnolence due to levetiracetam versus oxcarbazepine - a retrospective comparison study of North Indian patients with refractory epilepsy</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2016</year>
<volume>64, Part A</volume>
<fpage>216</fpage>
<lpage>218</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2016.08.005</pub-id>
<pub-id pub-id-type="other">2-s2.0-84991669558</pub-id>
<pub-id pub-id-type="pmid">27756024</pub-id>
</element-citation>
</ref>
<ref id="B72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wieshmann</surname>
<given-names>U. C.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>G. A.</given-names>
</name>
</person-group>
<article-title>Self-reported feelings of anger and aggression towards others in patients on levetiracetam: data from the UK antiepileptic drug register</article-title>
<source/>
<italic toggle="yes">BMJ Open</italic>
<year>2013</year>
<volume>3</volume>
<issue>3, article e002564</issue>
<pub-id pub-id-type="doi">10.1136/bmjopen-2013-002564</pub-id>
<pub-id pub-id-type="other">2-s2.0-84876116287</pub-id>
<pub-id pub-id-type="pmid">23516271</pub-id>
</element-citation>
</ref>
<ref id="B73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wieshmann</surname>
<given-names>U. C.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Efficacy and tolerability of anti-epileptic drugs-an internet study</article-title>
<source/>
<italic toggle="yes">Acta Neurologica Scandinavica</italic>
<year>2017</year>
<volume>135</volume>
<issue>5</issue>
<fpage>533</fpage>
<lpage>539</lpage>
<pub-id pub-id-type="doi">10.1111/ane.12698</pub-id>
<pub-id pub-id-type="other">2-s2.0-84991577460</pub-id>
<pub-id pub-id-type="pmid">27757951</pub-id>
</element-citation>
</ref>
<ref id="B74">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coyle</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Clough</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mohanraj</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Clinical experience with perampanel: focus on psychiatric adverse effects</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2014</year>
<volume>41</volume>
<fpage>193</fpage>
<lpage>196</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2014.09.072</pub-id>
<pub-id pub-id-type="other">2-s2.0-84910023591</pub-id>
<pub-id pub-id-type="pmid">25461214</pub-id>
</element-citation>
</ref>
<ref id="B75">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dolton</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Choudry</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Perampanel and challenging behaviour in intellectual disability and epilepsy: a management dilemma</article-title>
<source/>
<italic toggle="yes">Case Reports in Psychiatry</italic>
<year>2014</year>
<volume>2014</volume>
<fpage>3</fpage>
<pub-id pub-id-type="publisher-id">409209</pub-id>
<pub-id pub-id-type="doi">10.1155/2014/409209</pub-id>
</element-citation>
</ref>
<ref id="B76">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>French</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Krauss</surname>
<given-names>G. L.</given-names>
</name>
<name>
<surname>Wechsler</surname>
<given-names>R. T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy a randomized trial</article-title>
<source/>
<italic toggle="yes">Neurology</italic>
<year>2015</year>
<volume>85</volume>
<issue>11</issue>
<fpage>950</fpage>
<lpage>957</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0000000000001930</pub-id>
<pub-id pub-id-type="other">2-s2.0-84946509524</pub-id>
<pub-id pub-id-type="pmid">26296511</pub-id>
</element-citation>
</ref>
<ref id="B77">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krauss</surname>
<given-names>G. L.</given-names>
</name>
<name>
<surname>Perucca</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ben-Menachem</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2014</year>
<volume>55</volume>
<issue>7</issue>
<fpage>1058</fpage>
<lpage>1068</lpage>
<pub-id pub-id-type="doi">10.1111/epi.12643</pub-id>
<pub-id pub-id-type="other">2-s2.0-84904329205</pub-id>
<pub-id pub-id-type="pmid">24867391</pub-id>
</element-citation>
</ref>
<ref id="B78">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lagae</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Villanueva</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Meador</surname>
<given-names>K. J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: a randomized study evaluating behavior, efficacy, and safety</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2016</year>
<volume>57</volume>
<issue>7</issue>
<fpage>1120</fpage>
<lpage>1129</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13417</pub-id>
<pub-id pub-id-type="other">2-s2.0-84977582464</pub-id>
<pub-id pub-id-type="pmid">27221398</pub-id>
</element-citation>
</ref>
<ref id="B79">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinhoff</surname>
<given-names>B. J.</given-names>
</name>
<name>
<surname>Hamer</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Trinka</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria</article-title>
<source/>
<italic toggle="yes">Epilepsy Research</italic>
<year>2014</year>
<volume>108</volume>
<issue>5</issue>
<fpage>986</fpage>
<lpage>988</lpage>
<pub-id pub-id-type="doi">10.1016/j.eplepsyres.2014.03.015</pub-id>
<pub-id pub-id-type="other">2-s2.0-84900468332</pub-id>
<pub-id pub-id-type="pmid">24721197</pub-id>
</element-citation>
</ref>
<ref id="B80">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wehner</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Mannan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Turaga</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Retention of perampanel in adults with pharmacoresistant epilepsy at a single tertiary care center</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2017</year>
<volume>73</volume>
<fpage>106</fpage>
<lpage>110</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2017.04.006</pub-id>
<pub-id pub-id-type="other">2-s2.0-85020765552</pub-id>
<pub-id pub-id-type="pmid">28624720</pub-id>
</element-citation>
</ref>
<ref id="B81">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grosso</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Galimberti</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Farnetani</surname>
<given-names>M. A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Efficacy and safety of topiramate in infants according to epilepsy syndromes</article-title>
<source/>
<italic toggle="yes">Seizure</italic>
<year>2005</year>
<volume>14</volume>
<issue>3</issue>
<fpage>183</fpage>
<lpage>189</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2005.01.006</pub-id>
<pub-id pub-id-type="other">2-s2.0-20144366554</pub-id>
<pub-id pub-id-type="pmid">15797353</pub-id>
</element-citation>
</ref>
<ref id="B82">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanner</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Wuu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Faught</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tatum</surname>
<given-names>W. O.</given-names>
</name>
<name>
<surname>Fix</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>French</surname>
<given-names>J. A.</given-names>
</name>
</person-group>
<article-title>A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2003</year>
<volume>4</volume>
<issue>5</issue>
<fpage>548</fpage>
<lpage>552</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2003.07.007</pub-id>
<pub-id pub-id-type="other">2-s2.0-10744230559</pub-id>
<pub-id pub-id-type="pmid">14527497</pub-id>
</element-citation>
</ref>
<ref id="B83">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reith</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Burke</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Appleton</surname>
<given-names>D. B.</given-names>
</name>
<name>
<surname>Wallace</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pelekanos</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Tolerability of topiramate in children and adolescents</article-title>
<source/>
<italic toggle="yes">Journal of Paediatrics and Child Health</italic>
<year>2003</year>
<volume>39</volume>
<issue>6</issue>
<fpage>416</fpage>
<lpage>419</lpage>
<pub-id pub-id-type="doi">10.1046/j.1440-1754.2003.00180.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-0141682762</pub-id>
<pub-id pub-id-type="pmid">12919493</pub-id>
</element-citation>
</ref>
<ref id="B84">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cortes-Altamirano</surname>
<given-names>J. L.</given-names>
</name>
<name>
<surname>Olmos-Hernandez</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bonilla-Jaime</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bandala</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gonzalez-Maciel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Alfaro-Rodriguez</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Levetiracetam as an antiepileptic, neuroprotective, and hyperalgesic drug</article-title>
<source/>
<italic toggle="yes">Neurology India</italic>
<year>2016</year>
<volume>64</volume>
<issue>6</issue>
<fpage>1266</fpage>
<lpage>1275</lpage>
<pub-id pub-id-type="doi">10.4103/0028-3886.193801</pub-id>
<pub-id pub-id-type="other">2-s2.0-84997228965</pub-id>
<pub-id pub-id-type="pmid">27841198</pub-id>
</element-citation>
</ref>
<ref id="B85">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lyseng-Williamson</surname>
<given-names>K. A.</given-names>
</name>
</person-group>
<article-title>Spotlight on levetiracetam in epilepsy</article-title>
<source/>
<italic toggle="yes">CNS Drugs</italic>
<year>2011</year>
<volume>25</volume>
<issue>10</issue>
<fpage>901</fpage>
<lpage>905</lpage>
<pub-id pub-id-type="doi">10.2165/11208340-000000000-00000</pub-id>
<pub-id pub-id-type="other">2-s2.0-80053045911</pub-id>
<pub-id pub-id-type="pmid">21936590</pub-id>
</element-citation>
</ref>
<ref id="B86">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rogawski</surname>
<given-names>M. A.</given-names>
</name>
</person-group>
<article-title>Diverse mechanisms of antiepileptic drugs in the development pipeline</article-title>
<source/>
<italic toggle="yes">Epilepsy Research</italic>
<year>2006</year>
<volume>69</volume>
<issue>3</issue>
<fpage>273</fpage>
<lpage>294</lpage>
<pub-id pub-id-type="doi">10.1016/j.eplepsyres.2006.02.004</pub-id>
<pub-id pub-id-type="other">2-s2.0-33747049831</pub-id>
<pub-id pub-id-type="pmid">16621450</pub-id>
</element-citation>
</ref>
<ref id="B87">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carunchio</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Pieri</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ciotti</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Albo</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zona</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug levetiracetam</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2007</year>
<volume>48</volume>
<issue>4</issue>
<fpage>654</fpage>
<lpage>662</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2006.00973.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-34247145481</pub-id>
<pub-id pub-id-type="pmid">17284293</pub-id>
</element-citation>
</ref>
<ref id="B88">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Doelken</surname>
<given-names>M. T.</given-names>
</name>
<name>
<surname>Hammen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bogner</surname>
<given-names>W.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Alterations of intracerebral <italic>γ</italic>-aminobutyric acid (GABA) levels by titration with levetiracetam in patients with focal epilepsies</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2010</year>
<volume>51</volume>
<issue>8</issue>
<fpage>1477</fpage>
<lpage>1482</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2010.02544.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-77955325929</pub-id>
<pub-id pub-id-type="pmid">20345933</pub-id>
</element-citation>
</ref>
<ref id="B89">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luz Adriana</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Blanca Alcira</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Itzel Jatziri</surname>
<given-names>C. G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of levetiracetam on extracellular amino acid levels in the dorsal hippocampus of rats with temporal lobe epilepsy</article-title>
<source/>
<italic toggle="yes">Epilepsy Research</italic>
<year>2018</year>
<volume>140</volume>
<fpage>111</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="doi">10.1016/j.eplepsyres.2018.01.004</pub-id>
<pub-id pub-id-type="other">2-s2.0-85044381286</pub-id>
<pub-id pub-id-type="pmid">29331845</pub-id>
</element-citation>
</ref>
<ref id="B90">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rigo</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Hans</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents</article-title>
<source/>
<italic toggle="yes">British Journal of Pharmacology</italic>
<year>2002</year>
<volume>136</volume>
<issue>5</issue>
<fpage>659</fpage>
<lpage>672</lpage>
<pub-id pub-id-type="doi">10.1038/sj.bjp.0704766</pub-id>
<pub-id pub-id-type="other">2-s2.0-0035987775</pub-id>
<pub-id pub-id-type="pmid">12086975</pub-id>
</element-citation>
</ref>
<ref id="B91">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ueda</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Doi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nagatomo</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Tokumaru</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Takaki</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Willmore</surname>
<given-names>L. J.</given-names>
</name>
</person-group>
<article-title>Effect of levetiracetam on molecular regulation of hippocampal glutamate and GABA transporters in rats with chronic seizures induced by amygdalar FeCl3 injection</article-title>
<source/>
<italic toggle="yes">Brain Research</italic>
<year>2007</year>
<volume>1151</volume>
<fpage>55</fpage>
<lpage>61</lpage>
<pub-id pub-id-type="doi">10.1016/j.brainres.2007.03.021</pub-id>
<pub-id pub-id-type="other">2-s2.0-34248228678</pub-id>
<pub-id pub-id-type="pmid">17408599</pub-id>
</element-citation>
</ref>
<ref id="B92">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wakita</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kotani</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kogure</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Akaike</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Inhibition of excitatory synaptic transmission in hippocampal neurons by levetiracetam involves Zn<sup>2+</sup>-dependent GABA type a receptor–mediated presynaptic modulation</article-title>
<source/>
<italic toggle="yes">The Journal of Pharmacology and Experimental Therapeutics</italic>
<year>2014</year>
<volume>348</volume>
<issue>2</issue>
<fpage>246</fpage>
<lpage>259</lpage>
<pub-id pub-id-type="doi">10.1124/jpet.113.208751</pub-id>
<pub-id pub-id-type="other">2-s2.0-84893034656</pub-id>
<pub-id pub-id-type="pmid">24259680</pub-id>
</element-citation>
</ref>
<ref id="B93">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lynch</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Lambeng</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nocka</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam</article-title>
<source/>
<italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic>
<year>2004</year>
<volume>101</volume>
<issue>26</issue>
<fpage>9861</fpage>
<lpage>9866</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0308208101</pub-id>
<pub-id pub-id-type="other">2-s2.0-3042748137</pub-id>
<pub-id pub-id-type="pmid">15210974</pub-id>
</element-citation>
</ref>
<ref id="B94">
<label>94</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>C. Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C. C.</given-names>
</name>
<name>
<surname>Liou</surname>
<given-names>H. H.</given-names>
</name>
</person-group>
<article-title>Levetiracetam inhibits glutamate transmission through presynaptic P/Q-type calcium channels on the granule cells of the dentate gyrus</article-title>
<source/>
<italic toggle="yes">British Journal of Pharmacology</italic>
<year>2009</year>
<volume>158</volume>
<issue>7</issue>
<fpage>1753</fpage>
<lpage>1762</lpage>
<pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00463.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-71249152084</pub-id>
<pub-id pub-id-type="pmid">19888964</pub-id>
</element-citation>
</ref>
<ref id="B95">
<label>95</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinhoff</surname>
<given-names>B. J.</given-names>
</name>
<name>
<surname>Bacher</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bucurenciu</surname>
<given-names>I.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy—a monocenter survey</article-title>
<source/>
<italic toggle="yes">Seizure</italic>
<year>2017</year>
<volume>48</volume>
<fpage>11</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2017.03.010</pub-id>
<pub-id pub-id-type="other">2-s2.0-85016390430</pub-id>
<pub-id pub-id-type="pmid">28364655</pub-id>
</element-citation>
</ref>
<ref id="B96">
<label>96</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yates</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Fakhoury</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Eckhardt</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Borghs</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>D'Souza</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2015</year>
<volume>52, Part A</volume>
<fpage>165</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2015.09.005</pub-id>
<pub-id pub-id-type="other">2-s2.0-84942743446</pub-id>
<pub-id pub-id-type="pmid">26432008</pub-id>
</element-citation>
</ref>
<ref id="B97">
<label>97</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niespodziany</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Rigo</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Moonen</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Matagne</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Klitgaard</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wolff</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Brivaracetam does not modulate ionotropic channels activated by glutamate, <italic>γ</italic>‐aminobutyric acid, and glycine in hippocampal neurons</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2017</year>
<volume>58</volume>
<issue>11</issue>
<fpage>e157</fpage>
<lpage>e161</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13890</pub-id>
<pub-id pub-id-type="other">2-s2.0-85032730138</pub-id>
<pub-id pub-id-type="pmid">28850675</pub-id>
</element-citation>
</ref>
<ref id="B98">
<label>98</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Winblad</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Piracetam: a review of pharmacological properties and clinical uses</article-title>
<source/>
<italic toggle="yes">CNS Drug Reviews</italic>
<year>2005</year>
<volume>11</volume>
<issue>2</issue>
<fpage>169</fpage>
<lpage>182</lpage>
<pub-id pub-id-type="pmid">16007238</pub-id>
</element-citation>
</ref>
<ref id="B99">
<label>99</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname>
<given-names>A. H.</given-names>
</name>
<name>
<surname>Oswald</surname>
<given-names>R. E.</given-names>
</name>
</person-group>
<article-title>Piracetam defines a new binding site for allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptors</article-title>
<source/>
<italic toggle="yes">Journal of Medicinal Chemistry</italic>
<year>2010</year>
<volume>53</volume>
<issue>5</issue>
<fpage>2197</fpage>
<lpage>2203</lpage>
<pub-id pub-id-type="doi">10.1021/jm901905j</pub-id>
<pub-id pub-id-type="other">2-s2.0-77949386630</pub-id>
<pub-id pub-id-type="pmid">20163115</pub-id>
</element-citation>
</ref>
<ref id="B100">
<label>100</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Almeida</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Ferrari</surname>
<given-names>P. F.</given-names>
</name>
<name>
<surname>Parmigiani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Miczek</surname>
<given-names>K. A.</given-names>
</name>
</person-group>
<article-title>Escalated aggressive behavior: dopamine, serotonin and GABA</article-title>
<source/>
<italic toggle="yes">European Journal of Pharmacology</italic>
<year>2005</year>
<volume>526</volume>
<issue>1–3</issue>
<fpage>51</fpage>
<lpage>64</lpage>
<pub-id pub-id-type="doi">10.1016/j.ejphar.2005.10.004</pub-id>
<pub-id pub-id-type="other">2-s2.0-28544438925</pub-id>
<pub-id pub-id-type="pmid">16325649</pub-id>
</element-citation>
</ref>
<ref id="B101">
<label>101</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coccaro</surname>
<given-names>E. F.</given-names>
</name>
<name>
<surname>Fanning</surname>
<given-names>J. R.</given-names>
</name>
<name>
<surname>Phan</surname>
<given-names>K. L.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Serotonin and impulsive aggression</article-title>
<source/>
<italic toggle="yes">CNS Spectrums</italic>
<year>2015</year>
<volume>20</volume>
<issue>3</issue>
<fpage>295</fpage>
<lpage>302</lpage>
<pub-id pub-id-type="doi">10.1017/S1092852915000310</pub-id>
<pub-id pub-id-type="other">2-s2.0-84929751252</pub-id>
<pub-id pub-id-type="pmid">25997605</pub-id>
</element-citation>
</ref>
<ref id="B102">
<label>102</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Quadros</surname>
<given-names>I. M.</given-names>
</name>
<name>
<surname>de Almeida</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Miczek</surname>
<given-names>K. A.</given-names>
</name>
</person-group>
<article-title>Brain serotonin receptors and transporters: initiation vs. termination of escalated aggression</article-title>
<source/>
<italic toggle="yes">Psychopharmacology</italic>
<year>2011</year>
<volume>213</volume>
<issue>2-3</issue>
<fpage>183</fpage>
<lpage>212</lpage>
<pub-id pub-id-type="doi">10.1007/s00213-010-2000-y</pub-id>
<pub-id pub-id-type="other">2-s2.0-79952487507</pub-id>
<pub-id pub-id-type="pmid">20938650</pub-id>
</element-citation>
</ref>
<ref id="B103">
<label>103</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rudzinski</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Velez-Ruiz</surname>
<given-names>N. J.</given-names>
</name>
<name>
<surname>Gedzelman</surname>
<given-names>E. R.</given-names>
</name>
<name>
<surname>Mauricio</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Shih</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Karakis</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel</article-title>
<source/>
<italic toggle="yes">Journal of Investigative Medicine</italic>
<year>2016</year>
<volume>64</volume>
<issue>6</issue>
<fpage>1087</fpage>
<lpage>1101</lpage>
<pub-id pub-id-type="doi">10.1136/jim-2016-000151</pub-id>
<pub-id pub-id-type="other">2-s2.0-85006097024</pub-id>
<pub-id pub-id-type="pmid">27252470</pub-id>
</element-citation>
</ref>
<ref id="B104">
<label>104</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coccaro</surname>
<given-names>E. F.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vezina</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Cerebrospinal fluid glutamate concentration correlates with impulsive aggression in human subjects</article-title>
<source/>
<italic toggle="yes">Journal of Psychiatric Research</italic>
<year>2013</year>
<volume>47</volume>
<issue>9</issue>
<fpage>1247</fpage>
<lpage>1253</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpsychires.2013.05.001</pub-id>
<pub-id pub-id-type="other">2-s2.0-84880135857</pub-id>
<pub-id pub-id-type="pmid">23791397</pub-id>
</element-citation>
</ref>
<ref id="B105">
<label>105</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vekovischeva</surname>
<given-names>O. Y.</given-names>
</name>
<name>
<surname>Aitta-Aho</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Echenko</surname>
<given-names>O.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduced aggression in AMPA-type glutamate receptor GluR-A subunit-deficient mice</article-title>
<source/>
<italic toggle="yes">Genes, brain, and behavior</italic>
<year>2004</year>
<volume>3</volume>
<issue>5</issue>
<fpage>253</fpage>
<lpage>265</lpage>
<pub-id pub-id-type="doi">10.1111/j.1601-1848.2004.00075.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-4644314470</pub-id>
</element-citation>
</ref>
<ref id="B106">
<label>106</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vekovischeva</surname>
<given-names>O. Y.</given-names>
</name>
<name>
<surname>Aitta-aho</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Verbitskaya</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sandnabba</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Korpi</surname>
<given-names>E. R.</given-names>
</name>
</person-group>
<article-title>Acute effects of AMPA-type glutamate receptor antagonists on intermale social behavior in two mouse lines bidirectionally selected for offensive aggression</article-title>
<source/>
<italic toggle="yes">Pharmacology, Biochemistry, and Behavior</italic>
<year>2007</year>
<volume>87</volume>
<issue>2</issue>
<fpage>241</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="doi">10.1016/j.pbb.2007.04.020</pub-id>
<pub-id pub-id-type="other">2-s2.0-34250765367</pub-id>
</element-citation>
</ref>
<ref id="B107">
<label>107</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Araki</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ago</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Hasebe</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Involvement of prefrontal AMPA receptors in encounter stimulation-induced hyperactivity in isolation-reared mice</article-title>
<source/>
<italic toggle="yes">International Journal of Neuropsychopharmacology</italic>
<year>2014</year>
<volume>17</volume>
<issue>6</issue>
<fpage>883</fpage>
<lpage>893</lpage>
<pub-id pub-id-type="doi">10.1017/S1461145713001582</pub-id>
<pub-id pub-id-type="other">2-s2.0-84899982106</pub-id>
<pub-id pub-id-type="pmid">24405605</pub-id>
</element-citation>
</ref>
<ref id="B108">
<label>108</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Belozertseva</surname>
<given-names>I. V.</given-names>
</name>
<name>
<surname>Bespalov</surname>
<given-names>A. Y.</given-names>
</name>
</person-group>
<article-title>Effects of NMDA receptor channel blockade on aggression in isolated male mice</article-title>
<source/>
<italic toggle="yes">Aggressive Behavior</italic>
<year>1999</year>
<volume>25</volume>
<issue>5</issue>
<fpage>381</fpage>
<lpage>396</lpage>
<pub-id pub-id-type="doi">10.1002/(sici)1098-2337(1999)25:5&lt;381::aid-ab6&gt;3.0.co;2-b</pub-id>
</element-citation>
</ref>
<ref id="B109">
<label>109</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spritzer</surname>
<given-names>S. D.</given-names>
</name>
<name>
<surname>Bravo</surname>
<given-names>T. P.</given-names>
</name>
<name>
<surname>Drazkowski</surname>
<given-names>J. F.</given-names>
</name>
</person-group>
<article-title>Topiramate for treatment in patients with migraine and epilepsy</article-title>
<source/>
<italic toggle="yes">Headache</italic>
<year>2016</year>
<volume>56</volume>
<issue>6</issue>
<fpage>1081</fpage>
<lpage>1085</lpage>
<pub-id pub-id-type="doi">10.1111/head.12826</pub-id>
<pub-id pub-id-type="other">2-s2.0-84974678227</pub-id>
<pub-id pub-id-type="pmid">27122361</pub-id>
</element-citation>
</ref>
<ref id="B110">
<label>110</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shank</surname>
<given-names>R. P.</given-names>
</name>
<name>
<surname>Gardocki</surname>
<given-names>J. F.</given-names>
</name>
<name>
<surname>Streeter</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Maryanoff</surname>
<given-names>B. E.</given-names>
</name>
</person-group>
<article-title>An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2000</year>
<volume>41</volume>
<issue>s1</issue>
<fpage>3</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1157.2000.tb02163.x</pub-id>
</element-citation>
</ref>
<ref id="B111">
<label>111</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kudin</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Debska-Vielhaber</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Vielhaber</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Elger</surname>
<given-names>C. E.</given-names>
</name>
<name>
<surname>Kunz</surname>
<given-names>W. S.</given-names>
</name>
</person-group>
<article-title>The mechanism of neuroprotection by topiramate in an animal model of epilepsy</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2004</year>
<volume>45</volume>
<issue>12</issue>
<fpage>1478</fpage>
<lpage>1487</lpage>
<pub-id pub-id-type="doi">10.1111/j.0013-9580.2004.13504.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-10644267593</pub-id>
<pub-id pub-id-type="pmid">15571505</pub-id>
</element-citation>
</ref>
<ref id="B112">
<label>112</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carney</surname>
<given-names>P. W.</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>G. D.</given-names>
</name>
</person-group>
<article-title>Insights into the mechanisms of absence seizure generation provided by EEG with functional MRI</article-title>
<source/>
<italic toggle="yes">Frontiers in Neurology</italic>
<year>2014</year>
<volume>5, article 162</volume>
<pub-id pub-id-type="doi">10.3389/fneur.2014.00162</pub-id>
</element-citation>
</ref>
<ref id="B113">
<label>113</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baykan</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Juvenile myoclonic epilepsy as a spectrum disorder: a focused review</article-title>
<source/>
<italic toggle="yes">Seizure</italic>
<year>2017</year>
<volume>49</volume>
<fpage>36</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2017.05.011</pub-id>
<pub-id pub-id-type="other">2-s2.0-85019844998</pub-id>
<pub-id pub-id-type="pmid">28544889</pub-id>
</element-citation>
</ref>
<ref id="B114">
<label>114</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Syvertsen</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Thuve</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Stordrange</surname>
<given-names>B. S.</given-names>
</name>
<name>
<surname>Brodtkorb</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Clinical heterogeneity of juvenile myoclonic epilepsy: follow-up after an interval of more than 20 years</article-title>
<source/>
<italic toggle="yes">Seizure</italic>
<year>2014</year>
<volume>23</volume>
<issue>5</issue>
<fpage>344</fpage>
<lpage>348</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2014.01.012</pub-id>
<pub-id pub-id-type="other">2-s2.0-84899639090</pub-id>
<pub-id pub-id-type="pmid">24512779</pub-id>
</element-citation>
</ref>
<ref id="B115">
<label>115</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mula</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Monaco</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Antiepileptic drugs and psychopathology of epilepsy: an update</article-title>
<source/>
<italic toggle="yes">Epileptic Disorders</italic>
<year>2009</year>
<volume>11</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1684/epd.2009.0238</pub-id>
<pub-id pub-id-type="other">2-s2.0-65349157662</pub-id>
<pub-id pub-id-type="pmid">19258231</pub-id>
</element-citation>
</ref>
<ref id="B116">
<label>116</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marsh</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Krauss</surname>
<given-names>G. L.</given-names>
</name>
</person-group>
<article-title>Aggression and violence in patients with epilepsy</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2000</year>
<volume>1</volume>
<issue>3</issue>
<fpage>160</fpage>
<lpage>168</lpage>
<pub-id pub-id-type="doi">10.1006/ebeh.2000.0061</pub-id>
<pub-id pub-id-type="other">2-s2.0-0001589461</pub-id>
<pub-id pub-id-type="pmid">12609149</pub-id>
</element-citation>
</ref>
<ref id="B117">
<label>117</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mula</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The interictal dysphoric disorder of epilepsy: legend or reality?</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2016</year>
<volume>58</volume>
<fpage>7</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2016.02.018</pub-id>
<pub-id pub-id-type="other">2-s2.0-84960885064</pub-id>
<pub-id pub-id-type="pmid">26991746</pub-id>
</element-citation>
</ref>
<ref id="B118">
<label>118</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berg</surname>
<given-names>A. T.</given-names>
</name>
<name>
<surname>Altalib</surname>
<given-names>H. H.</given-names>
</name>
<name>
<surname>Devinsky</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Psychiatric and behavioral comorbidities in epilepsy: a critical reappraisal</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2017</year>
<volume>58</volume>
<issue>7</issue>
<fpage>1123</fpage>
<lpage>1130</lpage>
<pub-id pub-id-type="doi">10.1111/epi.13766</pub-id>
<pub-id pub-id-type="other">2-s2.0-85018781739</pub-id>
<pub-id pub-id-type="pmid">28464309</pub-id>
</element-citation>
</ref>
<ref id="B119">
<label>119</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devinsky</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Postictal psychosis: common, dangerous, and treatable</article-title>
<source/>
<italic toggle="yes">Epilepsy Currents</italic>
<year>2008</year>
<volume>8</volume>
<issue>2</issue>
<fpage>31</fpage>
<lpage>34</lpage>
<pub-id pub-id-type="doi">10.1111/j.1535-7511.2008.00227.x</pub-id>
<pub-id pub-id-type="pmid">18330462</pub-id>
</element-citation>
</ref>
<ref id="B120">
<label>120</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eisenschenk</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Krop</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Devinsky</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Homicide during postictal psychosis</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior Case Reports</italic>
<year>2014</year>
<volume>2</volume>
<fpage>118</fpage>
<lpage>120</lpage>
<pub-id pub-id-type="doi">10.1016/j.ebcr.2014.04.001</pub-id>
<pub-id pub-id-type="other">2-s2.0-84899867958</pub-id>
<pub-id pub-id-type="pmid">25667886</pub-id>
</element-citation>
</ref>
<ref id="B121">
<label>121</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mullen</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Carvill</surname>
<given-names>G. L.</given-names>
</name>
<name>
<surname>Bellows</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Copy number variants are frequent in genetic generalized epilepsy with intellectual disability</article-title>
<source/>
<italic toggle="yes">Neurology</italic>
<year>2013</year>
<volume>81</volume>
<issue>17</issue>
<fpage>1507</fpage>
<lpage>1514</lpage>
<pub-id pub-id-type="doi">10.1212/WNL.0b013e3182a95829</pub-id>
<pub-id pub-id-type="other">2-s2.0-84888253405</pub-id>
<pub-id pub-id-type="pmid">24068782</pub-id>
</element-citation>
</ref>
<ref id="B122">
<label>122</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnson</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Shorvon</surname>
<given-names>S. D.</given-names>
</name>
</person-group>
<article-title>Heredity in epilepsy: neurodevelopment, comorbidity, and the neurological trait</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2011</year>
<volume>22</volume>
<issue>3</issue>
<fpage>421</fpage>
<lpage>427</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2011.07.031</pub-id>
<pub-id pub-id-type="other">2-s2.0-80054975052</pub-id>
<pub-id pub-id-type="pmid">21890419</pub-id>
</element-citation>
</ref>
<ref id="B123">
<label>123</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torres</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Barbosa</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Maciel</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Recurrent copy number variations as risk factors for neurodevelopmental disorders: critical overview and analysis of clinical implications</article-title>
<source/>
<italic toggle="yes">Journal of Medical Genetics</italic>
<year>2016</year>
<volume>53</volume>
<issue>2</issue>
<fpage>73</fpage>
<lpage>90</lpage>
<pub-id pub-id-type="doi">10.1136/jmedgenet-2015-103366</pub-id>
<pub-id pub-id-type="other">2-s2.0-84958836351</pub-id>
<pub-id pub-id-type="pmid">26502893</pub-id>
</element-citation>
</ref>
<ref id="B124">
<label>124</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vlaskamp</surname>
<given-names>D. R. M.</given-names>
</name>
<name>
<surname>Callenbach</surname>
<given-names>P. M. C.</given-names>
</name>
<name>
<surname>Rump</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Copy number variation in a hospital-based cohort of children with epilepsy</article-title>
<source/>
<italic toggle="yes">Epilepsia Open</italic>
<year>2017</year>
<volume>2</volume>
<issue>2</issue>
<fpage>244</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="doi">10.1002/epi4.12057</pub-id>
<pub-id pub-id-type="pmid">29588953</pub-id>
</element-citation>
</ref>
<ref id="B125">
<label>125</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Helmstaedter</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mihov</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Toliat</surname>
<given-names>M. R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2013</year>
<volume>54</volume>
<issue>1</issue>
<fpage>36</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2012.03603.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-84872095204</pub-id>
<pub-id pub-id-type="pmid">22881836</pub-id>
</element-citation>
</ref>
<ref id="B126">
<label>126</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Brodtkorb</surname>
<given-names>E.</given-names>
</name>
</person-group>
<person-group person-group-type="editor">
<name>
<surname>Shorvon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Perucca</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Engel</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Management of epilepsy in people with intellectual disabilities</article-title>
<source/>
<italic toggle="yes">The Treatment of Epilepsi</italic>
<year>2016</year>
<edition>4</edition>
<publisher-loc>Chichester</publisher-loc>
<publisher-name>John Wiley &amp; Sons</publisher-name>
<fpage>193</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="doi">10.1002/9781118936979.ch15</pub-id>
</element-citation>
</ref>
<ref id="B127">
<label>127</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Besag</surname>
<given-names>F. M.</given-names>
</name>
</person-group>
<article-title>Behavioural effects of the newer antiepileptic drugs: an update</article-title>
<source/>
<italic toggle="yes">Expert Opinion on Drug Safety</italic>
<year>2004</year>
<volume>3</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="doi">10.1517/14740338.3.1.1</pub-id>
<pub-id pub-id-type="other">2-s2.0-2142705671</pub-id>
<pub-id pub-id-type="pmid">14680457</pub-id>
</element-citation>
</ref>
<ref id="B128">
<label>128</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loring</surname>
<given-names>D. W.</given-names>
</name>
<name>
<surname>Marino</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Meador</surname>
<given-names>K. J.</given-names>
</name>
</person-group>
<article-title>Neuropsychological and behavioral effects of antiepilepsy drugs</article-title>
<source/>
<italic toggle="yes">Neuropsychology Review</italic>
<year>2007</year>
<volume>17</volume>
<issue>4</issue>
<fpage>413</fpage>
<lpage>425</lpage>
<pub-id pub-id-type="doi">10.1007/s11065-007-9043-9</pub-id>
<pub-id pub-id-type="other">2-s2.0-36849006900</pub-id>
<pub-id pub-id-type="pmid">17943448</pub-id>
</element-citation>
</ref>
<ref id="B129">
<label>129</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Witt</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Elger</surname>
<given-names>C. E.</given-names>
</name>
<name>
<surname>Helmstaedter</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Impaired verbal fluency under topiramate--evidence for synergistic negative effects of epilepsy, topiramate, and polytherapy</article-title>
<source/>
<italic toggle="yes">European Journal of Neurology</italic>
<year>2013</year>
<volume>20</volume>
<issue>1</issue>
<fpage>130</fpage>
<lpage>137</lpage>
<pub-id pub-id-type="doi">10.1111/j.1468-1331.2012.03814.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-84871645069</pub-id>
<pub-id pub-id-type="pmid">22827489</pub-id>
</element-citation>
</ref>
<ref id="B130">
<label>130</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Birger</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Swartz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Alesh</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Grishpan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Kotelr</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Aggression: the testosterone-serotonin link</article-title>
<source/>
<italic toggle="yes">Israel Medical Association Journal</italic>
<year>2003</year>
<volume>5</volume>
<issue>9</issue>
<fpage>653</fpage>
<lpage>658</lpage>
<pub-id pub-id-type="pmid">14509157</pub-id>
</element-citation>
</ref>
<ref id="B131">
<label>131</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carre</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Geniole</surname>
<given-names>S. N.</given-names>
</name>
<name>
<surname>Ortiz</surname>
<given-names>T. L.</given-names>
</name>
<name>
<surname>Bird</surname>
<given-names>B. M.</given-names>
</name>
<name>
<surname>Videto</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bonin</surname>
<given-names>P. L.</given-names>
</name>
</person-group>
<article-title>Exogenous testosterone rapidly increases aggressive behavior in dominant and impulsive men</article-title>
<source/>
<italic toggle="yes">Biological Psychiatry</italic>
<year>2017</year>
<volume>82</volume>
<issue>4</issue>
<fpage>249</fpage>
<lpage>256</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2016.06.009</pub-id>
<pub-id pub-id-type="other">2-s2.0-84981737276</pub-id>
<pub-id pub-id-type="pmid">27524498</pub-id>
</element-citation>
</ref>
<ref id="B132">
<label>132</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Swann</surname>
<given-names>A. C.</given-names>
</name>
</person-group>
<article-title>Neuroreceptor mechanisms of aggression and its treatment</article-title>
<source/>
<italic toggle="yes">Journal of Clinical Psychiatry</italic>
<year>2003</year>
<volume>64</volume>
<issue>a4</issue>
<fpage>26</fpage>
<lpage>35</lpage>
<pub-id pub-id-type="pmid">12672262</pub-id>
</element-citation>
</ref>
<ref id="B133">
<label>133</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clark</surname>
<given-names>A. S.</given-names>
</name>
<name>
<surname>Henderson</surname>
<given-names>L. P.</given-names>
</name>
</person-group>
<article-title>Behavioral and physiological responses to anabolic-androgenic steroids</article-title>
<source/>
<italic toggle="yes">Neuroscience and Biobehavioral Reviews</italic>
<year>2003</year>
<volume>27</volume>
<issue>5</issue>
<fpage>413</fpage>
<lpage>436</lpage>
<pub-id pub-id-type="doi">10.1016/s0149-7634(03)00064-2</pub-id>
<pub-id pub-id-type="other">2-s2.0-0141497464</pub-id>
<pub-id pub-id-type="pmid">14505684</pub-id>
</element-citation>
</ref>
<ref id="B134">
<label>134</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodin</surname>
<given-names>E. A.</given-names>
</name>
</person-group>
<article-title>Psychomotor epilepsy and aggressive behavior</article-title>
<source/>
<italic toggle="yes">Archives of General Psychiatry</italic>
<year>1973</year>
<volume>28</volume>
<issue>2</issue>
<fpage>210</fpage>
<lpage>213</lpage>
<pub-id pub-id-type="doi">10.1001/archpsyc.1973.01750320044007</pub-id>
<pub-id pub-id-type="other">2-s2.0-0015578858</pub-id>
<pub-id pub-id-type="pmid">4684286</pub-id>
</element-citation>
</ref>
<ref id="B135">
<label>135</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandya</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Vrbancic</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ladino</surname>
<given-names>L. D.</given-names>
</name>
<name>
<surname>Tellez-Zenteno</surname>
<given-names>J. F.</given-names>
</name>
</person-group>
<article-title>Epilepsy and homicide</article-title>
<source/>
<italic toggle="yes">Neuropsychiatric Disease and Treatment</italic>
<year>2013</year>
<volume>9</volume>
<fpage>667</fpage>
<lpage>673</lpage>
<pub-id pub-id-type="doi">10.2147/NDT.S45370</pub-id>
<pub-id pub-id-type="other">2-s2.0-84877941821</pub-id>
<pub-id pub-id-type="pmid">23700367</pub-id>
</element-citation>
</ref>
<ref id="B136">
<label>136</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piazzini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Edefonti</surname>
<given-names>V.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A new Italian instrument for the assessment of irritability in patients with epilepsy</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2011</year>
<volume>21</volume>
<issue>3</issue>
<fpage>275</fpage>
<lpage>281</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2011.04.051</pub-id>
<pub-id pub-id-type="other">2-s2.0-79959622436</pub-id>
<pub-id pub-id-type="pmid">21624849</pub-id>
</element-citation>
</ref>
<ref id="B137">
<label>137</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Reimers</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>New antiepileptic drugs and women</article-title>
<source/>
<italic toggle="yes">Seizure</italic>
<year>2014</year>
<volume>23</volume>
<issue>8</issue>
<fpage>585</fpage>
<lpage>591</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2014.05.004</pub-id>
<pub-id pub-id-type="other">2-s2.0-84906314492</pub-id>
<pub-id pub-id-type="pmid">24908139</pub-id>
</element-citation>
</ref>
<ref id="B138">
<label>138</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Svalheim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sveberg</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Mochol</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tauboll</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Interactions between antiepileptic drugs and hormones</article-title>
<source/>
<italic toggle="yes">Seizure</italic>
<year>2015</year>
<volume>28</volume>
<fpage>12</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1016/j.seizure.2015.02.022</pub-id>
<pub-id pub-id-type="other">2-s2.0-84929287029</pub-id>
<pub-id pub-id-type="pmid">25797888</pub-id>
</element-citation>
</ref>
<ref id="B139">
<label>139</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maguire</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Salpekar</surname>
<given-names>J. A.</given-names>
</name>
</person-group>
<article-title>Stress, seizures, and hypothalamic–pituitary–adrenal axis targets for the treatment of epilepsy</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2013</year>
<volume>26</volume>
<issue>3</issue>
<fpage>352</fpage>
<lpage>362</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2012.09.040</pub-id>
<pub-id pub-id-type="other">2-s2.0-84875236129</pub-id>
<pub-id pub-id-type="pmid">23200771</pub-id>
</element-citation>
</ref>
<ref id="B140">
<label>140</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Summers</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Winberg</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Interactions between the neural regulation of stress and aggression</article-title>
<source/>
<italic toggle="yes">The Journal of Experimental Biology</italic>
<year>2006</year>
<volume>209</volume>
<issue>23</issue>
<fpage>4581</fpage>
<lpage>4589</lpage>
<pub-id pub-id-type="doi">10.1242/jeb.02565</pub-id>
<pub-id pub-id-type="other">2-s2.0-33845964605</pub-id>
<pub-id pub-id-type="pmid">17114393</pub-id>
</element-citation>
</ref>
<ref id="B141">
<label>141</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berger</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Kouzarides</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Shiekhattar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shilatifard</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>An operational definition of epigenetics</article-title>
<source/>
<italic toggle="yes">Genes &amp; Development</italic>
<year>2009</year>
<volume>23</volume>
<issue>7</issue>
<fpage>781</fpage>
<lpage>783</lpage>
<pub-id pub-id-type="doi">10.1101/gad.1787609</pub-id>
<pub-id pub-id-type="other">2-s2.0-64349095390</pub-id>
<pub-id pub-id-type="pmid">19339683</pub-id>
</element-citation>
</ref>
<ref id="B142">
<label>142</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elvir</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Duclot</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Kabbaj</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Epigenetic regulation of motivated behaviors by histone deacetylase inhibitors</article-title>
<source/>
<italic toggle="yes">Neuroscience and Biobehavioral Reviews</italic>
<year>2017</year>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2017.09.030</pub-id>
<pub-id pub-id-type="other">2-s2.0-85032723830</pub-id>
</element-citation>
</ref>
<ref id="B143">
<label>143</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eyal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yagen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sobol</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Altschuler</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shmuel</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bialer</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>The activity of antiepileptic drugs as histone deacetylase inhibitors</article-title>
<source/>
<italic toggle="yes">Epilepsia</italic>
<year>2004</year>
<volume>45</volume>
<issue>7</issue>
<fpage>737</fpage>
<lpage>744</lpage>
<pub-id pub-id-type="doi">10.1111/j.0013-9580.2004.00104.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-3042859183</pub-id>
<pub-id pub-id-type="pmid">15230695</pub-id>
</element-citation>
</ref>
<ref id="B144">
<label>144</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Landolt</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Some clinical electroencephalographic correlations in epileptic psychoses (twilight states)</article-title>
<source/>
<italic toggle="yes">Electroencephalography and Clinical Neurophysiology</italic>
<year>1953</year>
<volume>5</volume>
<fpage>p. 121</fpage>
</element-citation>
</ref>
<ref id="B145">
<label>145</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glauser</surname>
<given-names>T. A.</given-names>
</name>
</person-group>
<article-title>Effects of antiepileptic medications on psychiatric and behavioral comorbidities in children and adolescents with epilepsy</article-title>
<source/>
<italic toggle="yes">Epilepsy &amp; Behavior</italic>
<year>2004</year>
<volume>5</volume>
<issue>Supplement 3</issue>
<fpage>25</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="doi">10.1016/j.yebeh.2004.06.013</pub-id>
<pub-id pub-id-type="other">2-s2.0-16544366951</pub-id>
</element-citation>
</ref>
<ref id="B146">
<label>146</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawakami</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Itoh</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Forced normalization: antagonism between epilepsy and psychosis</article-title>
<source/>
<italic toggle="yes">Pediatric Neurology</italic>
<year>2017</year>
<volume>70</volume>
<fpage>16</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2017.02.007</pub-id>
<pub-id pub-id-type="other">2-s2.0-85018276279</pub-id>
<pub-id pub-id-type="pmid">28460793</pub-id>
</element-citation>
</ref>
<ref id="B147">
<label>147</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loganathan</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Enja</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lippmann</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>FORCED NORMALIZATION: epilepsy and psychosis interaction</article-title>
<source/>
<italic toggle="yes">Innovations in Clinical Neuroscience</italic>
<year>2015</year>
<volume>12</volume>
<issue>5-6</issue>
<fpage>38</fpage>
<lpage>41</lpage>
<pub-id pub-id-type="pmid">26155377</pub-id>
</element-citation>
</ref>
<ref id="B148">
<label>148</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baran</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bitter</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Ungvari</surname>
<given-names>G. S.</given-names>
</name>
<name>
<surname>Gazdag</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>The birth of convulsive therapy revisited: a reappraisal of Laszlo Meduna’s first cohort of patients</article-title>
<source/>
<italic toggle="yes">Journal of Affective Disorders</italic>
<year>2012</year>
<volume>136</volume>
<issue>3</issue>
<fpage>1179</fpage>
<lpage>1182</lpage>
<pub-id pub-id-type="doi">10.1016/j.jad.2011.11.045</pub-id>
<pub-id pub-id-type="other">2-s2.0-84857364161</pub-id>
<pub-id pub-id-type="pmid">22230354</pub-id>
</element-citation>
</ref>
<ref id="B149">
<label>149</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Topkan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bilen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Titiz</surname>
<given-names>A. P.</given-names>
</name>
<name>
<surname>Eruyar</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ak</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Forced normalization: an overlooked entity in epileptic patients</article-title>
<source/>
<italic toggle="yes">Asian Journal of Psychiatry</italic>
<year>2016</year>
<volume>23</volume>
<fpage>93</fpage>
<lpage>94</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajp.2016.07.017</pub-id>
<pub-id pub-id-type="other">2-s2.0-84979888016</pub-id>
<pub-id pub-id-type="pmid">27969087</pub-id>
</element-citation>
</ref>
<ref id="B150">
<label>150</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Longo</surname>
<given-names>L. P.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives</article-title>
<source/>
<italic toggle="yes">American Family Physician</italic>
<year>2000</year>
<volume>61</volume>
<issue>7</issue>
<fpage>2121</fpage>
<lpage>2128</lpage>
<pub-id pub-id-type="pmid">10779253</pub-id>
</element-citation>
</ref>
<ref id="B151">
<label>151</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Guski</surname>
<given-names>L. S.</given-names>
</name>
<name>
<surname>Freund</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gotzsche</surname>
<given-names>P. C.</given-names>
</name>
</person-group>
<article-title>Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports</article-title>
<source/>
<italic toggle="yes">BMJ</italic>
<year>2016</year>
<volume>352</volume>
<fpage>p. i65</fpage>
<pub-id pub-id-type="doi">10.1136/bmj.i65</pub-id>
<pub-id pub-id-type="other">2-s2.0-84959289840</pub-id>
</element-citation>
</ref>
<ref id="B152">
<label>152</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stuckelman</surname>
<given-names>Z. D.</given-names>
</name>
<name>
<surname>Mulqueen</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Ferracioli-Oda</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Risk of irritability with psychostimulant treatment in children with ADHD: a meta-analysis</article-title>
<source/>
<italic toggle="yes">The Journal of Clinical Psychiatry</italic>
<year>2017</year>
<volume>78</volume>
<issue>6</issue>
<fpage>e648</fpage>
<lpage>e655</lpage>
<pub-id pub-id-type="doi">10.4088/JCP.15r10601</pub-id>
<pub-id pub-id-type="other">2-s2.0-85025085173</pub-id>
<pub-id pub-id-type="pmid">28682529</pub-id>
</element-citation>
</ref>
<ref id="B153">
<label>153</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Varghese</surname>
<given-names>B. S.</given-names>
</name>
<name>
<surname>Rajeev</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Norrish</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Khusaiby</surname>
<given-names>S. B.</given-names>
</name>
</person-group>
<article-title>Topiramate for anger control: a systematic review</article-title>
<source/>
<italic toggle="yes">Indian Journal of Pharmacology</italic>
<year>2010</year>
<volume>42</volume>
<issue>3</issue>
<fpage>135</fpage>
<lpage>141</lpage>
<pub-id pub-id-type="doi">10.4103/0253-7613.66834</pub-id>
<pub-id pub-id-type="other">2-s2.0-77955456607</pub-id>
<pub-id pub-id-type="pmid">20871762</pub-id>
</element-citation>
</ref>
<ref id="B154">
<label>154</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Vries</surname>
<given-names>T. W.</given-names>
</name>
<name>
<surname>van Hunsel</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Adverse drug reactions of systemic antihistamines in children in the Netherlands</article-title>
<source/>
<italic toggle="yes">Archives of Disease in Childhood</italic>
<year>2016</year>
<volume>101</volume>
<issue>10</issue>
<fpage>968</fpage>
<lpage>970</lpage>
<pub-id pub-id-type="doi">10.1136/archdischild-2015-310315</pub-id>
<pub-id pub-id-type="other">2-s2.0-84964884090</pub-id>
<pub-id pub-id-type="pmid">27091848</pub-id>
</element-citation>
</ref>
<ref id="B155">
<label>155</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Golomb</surname>
<given-names>B. A.</given-names>
</name>
<name>
<surname>Kane</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Dimsdale</surname>
<given-names>J. E.</given-names>
</name>
</person-group>
<article-title>Severe irritability associated with statin cholesterol-lowering drugs</article-title>
<source/>
<italic toggle="yes">QJM</italic>
<year>2004</year>
<volume>97</volume>
<issue>4</issue>
<fpage>229</fpage>
<lpage>235</lpage>
<pub-id pub-id-type="doi">10.1093/qjmed/hch035</pub-id>
<pub-id pub-id-type="other">2-s2.0-1842844488</pub-id>
<pub-id pub-id-type="pmid">15028853</pub-id>
</element-citation>
</ref>
<ref id="B156">
<label>156</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morrison</surname>
<given-names>T. R.</given-names>
</name>
<name>
<surname>Sikes</surname>
<given-names>R. W.</given-names>
</name>
<name>
<surname>Melloni</surname>
<given-names>R. H.</given-names>
<suffix>Jr.</suffix>
</name>
</person-group>
<article-title>Anabolic steroids alter the physiological activity of aggression circuits in the lateral anterior hypothalamus</article-title>
<source/>
<italic toggle="yes">Neuroscience</italic>
<year>2016</year>
<volume>315</volume>
<fpage>1</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2015.12.001</pub-id>
<pub-id pub-id-type="other">2-s2.0-84950323592</pub-id>
<pub-id pub-id-type="pmid">26691962</pub-id>
</element-citation>
</ref>
<ref id="B157">
<label>157</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salas-Ramirez</surname>
<given-names>K. Y.</given-names>
</name>
<name>
<surname>Montalto</surname>
<given-names>P. R.</given-names>
</name>
<name>
<surname>Sisk</surname>
<given-names>C. L.</given-names>
</name>
</person-group>
<article-title>Anabolic steroids have long-lasting effects on male social behaviors</article-title>
<source/>
<italic toggle="yes">Behavioural Brain Research</italic>
<year>2010</year>
<volume>208</volume>
<issue>2</issue>
<fpage>328</fpage>
<lpage>335</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbr.2009.11.026</pub-id>
<pub-id pub-id-type="other">2-s2.0-77249176078</pub-id>
<pub-id pub-id-type="pmid">20036695</pub-id>
</element-citation>
</ref>
<ref id="B158">
<label>158</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carrillo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ricci</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Melloni</surname>
<given-names>R. H.</given-names>
</name>
</person-group>
<article-title>Glutamate-vasopressin interactions and the neurobiology of anabolic steroid-induced offensive aggression</article-title>
<source/>
<italic toggle="yes">Neuroscience</italic>
<year>2011</year>
<volume>185</volume>
<fpage>85</fpage>
<lpage>96</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroscience.2011.03.056</pub-id>
<pub-id pub-id-type="other">2-s2.0-79956262843</pub-id>
<pub-id pub-id-type="pmid">21459130</pub-id>
</element-citation>
</ref>
<ref id="B159">
<label>159</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jenkins</surname>
<given-names>B. G.</given-names>
</name>
</person-group>
<article-title>Pharmacologic magnetic resonance imaging (phMRI): imaging drug action in the brain</article-title>
<source/>
<italic toggle="yes">NeuroImage</italic>
<year>2012</year>
<volume>62</volume>
<issue>2</issue>
<fpage>1072</fpage>
<lpage>1085</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuroimage.2012.03.075</pub-id>
<pub-id pub-id-type="other">2-s2.0-84863009508</pub-id>
<pub-id pub-id-type="pmid">22495143</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="fig1" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>Summary of factors involved in aggressive behavior associated with antiepileptic drug treatment of epilepsy.</p>
</caption>
<graphic xlink:href="BN2018-2064027.001"></graphic>
</fig>
<table-wrap id="tab1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<p>Frequencies<sup>∗</sup> of various psychiatric and behavioral adverse effects of levetiracetam, perampanel, and topiramate according to their European SPCs [<xref ref-type="bibr" rid="B24">24</xref>–<xref ref-type="bibr" rid="B26">26</xref>].</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th colspan="1" rowspan="1"></th>
<th align="center" colspan="1" rowspan="1">Adverse effect</th>
<th align="center" colspan="1" rowspan="1">Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Levetiracetam</td>
<td align="center" colspan="1" rowspan="1">
<italic>Common</italic>:<break></break>Depression, <bold>hostility/aggression</bold>, anxiety, insomnia, nervousness/<bold>irritability</bold><break></break><italic>Uncommon</italic>:<break></break>Suicide attempt, suicidal ideation, psychotic disorder, abnormal behavior, hallucination, <bold>anger</bold>, confusion, panic attack, affect lability/mood swings, agitation<break></break><italic>Rare</italic>:<break></break>Completed suicide, personality disorder, thinking abnormal</td>
<td align="center" colspan="1" rowspan="1">Higher prevalence in children and adolescents than in adults: agitation (3.4%), mood swings (2.1%), affect lability (1.7%), aggression (8.2%), abnormal behavior (5.6%)</td>
</tr>
<tr>
<td align="center" colspan="3" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Perampanel</td>
<td align="center" colspan="1" rowspan="1">
<italic>Common</italic>:<break></break><bold>Aggression</bold>, <bold>anger</bold>, anxiety, confusion, <bold>irritability</bold><break></break><italic>Uncommon</italic>:<break></break>Suicidal ideation, suicide attempt</td>
<td align="center" colspan="1" rowspan="1">Aggression more frequently observed in adolescents than in adults</td>
</tr>
<tr>
<td align="center" colspan="3" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Topiramate</td>
<td align="center" colspan="1" rowspan="1">
<italic>Very common</italic>:<break></break>Depression<break></break><italic>Common</italic>:<break></break><bold>Irritability</bold>, bradyphrenia, insomnia, <bold>expressive language disorder</bold>, anxiety, confusion, disorientation, <bold>aggression</bold>, mood altered, agitation, mood swings, depressed mood, <bold>anger</bold>, abnormal behavior<break></break><italic>Uncommon</italic>:<break></break>Suicidal ideation, suicide attempt, hallucination, psychotic disorder, hallucination auditory, hallucination visual, apathy, lack of spontaneous speech, sleep disorder, affect lability, libido decreased, restlessness, crying, dysphemia, euphoric mood, paranoia, perseveration, panic attack, tearfulness, reading disorder, initial insomnia, flat affect, thinking abnormal, loss of libido, listless, middle insomnia, distractibility, early morning awakening, panic reaction, elevated mood<break></break><italic>Rare</italic>:<break></break>Mania, panic disorder, feeling of despair, hypomania</td>
<td align="center" colspan="1" rowspan="1">Irritability and expressive language among the most common adverse effects (&gt;5%)<break></break>Higher prevalence in children than in adults (&gt;2 times): suicidal ideation, abnormal behavior, aggression</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>
<sup>∗</sup>Very common: ≥1/10, common: ≥1/100 to &lt;1/10, uncommon: ≥1/1000 to &lt;1/100, rare: &lt;1/1000.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tab2" orientation="portrait" position="float">
<label>Table 2</label>
<caption>
<p>Studies reporting psychiatric and behavioral adverse reactions to levetiracetam.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Study</th>
<th align="center" colspan="1" rowspan="1">Study design</th>
<th align="center" colspan="1" rowspan="1">Study population</th>
<th align="center" colspan="1" rowspan="1">Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Brodtkorb et al. 2004 [<xref ref-type="bibr" rid="B57">57</xref>]</td>
<td align="center" colspan="1" rowspan="1">Cohort study, <italic>t</italic> = 8.1 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 184 adults (mean age: 34.7 years), of which 56 have intellectual disability</td>
<td align="center" colspan="1" rowspan="1">PBAR (aggression, irritability, mood swings, anxiety, restlessness, and psychotic symptoms) were among the most frequent adverse reactions. More frequent in patients with intellectual disability (23% vs. 10%).</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Chen et al. 2017 [<xref ref-type="bibr" rid="B19">19</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = 1–15 years</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 922 (2–18 years) with epilepsy; mono- or polytherapy</td>
<td align="center" colspan="1" rowspan="1">PBAR in 13.8%, leading to dose reduction or discontinuation in 11.2%. LEV with the highest frequency of PBAR (16.2%), leading to dose reduction or discontinuation in 6.7%.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Chen et al. 2017 [<xref ref-type="bibr" rid="B18">18</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = ≥12 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 4085 adults (mean age 41 years) with epilepsy; mono- or polytherapy of which LEV: 1890</td>
<td align="center" colspan="1" rowspan="1">PBAR in 17.2%, leading to dose reduction or discontinuation in 13.8%. LEV with the highest frequency of these adverse reactions (22.1%), leading to dose reduction in 17.7%.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Chung et al. 2007 [<xref ref-type="bibr" rid="B50">50</xref>]</td>
<td align="center" colspan="1" rowspan="1">Cohort study, <italic>t</italic> = 2 years</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 828 adults (mean age 38.5 years) (LEV: 196; LTG: 251; OXC: 97; TPM: 156; ZNS: 128)</td>
<td align="center" colspan="1" rowspan="1">Discontinuation due to PBAR in 19% using LEV (vs. 2–7% with LTG, OXC, TPM, and ZNS).</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ciesielski et al. 2006 [<xref ref-type="bibr" rid="B58">58</xref>]</td>
<td align="center" colspan="1" rowspan="1">Cohort study, <italic>t</italic> = 2 weeks</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 20 (22–52 years) with epilepsy (LEV: 10, PGB: 10)</td>
<td align="center" colspan="1" rowspan="1">No difference in neuropsychological tests after short-term treatment with LEV or PGB.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Cramer et al. 2003 [<xref ref-type="bibr" rid="B32">32</xref>]</td>
<td align="center" colspan="1" rowspan="1">Review article, <italic>t</italic> = &gt;2 years</td>
<td align="center" colspan="1" rowspan="1">Total <italic>n</italic> = 4179 adults (epilepsy, cognitive disorders, and anxiety) of which LEV: 2871, placebo: 1308</td>
<td align="center" colspan="1" rowspan="1">PBAR in 25.4% of 1393 patients using LEV (vs. 6.2% with placebo), including agitation (1.6% vs. 0.2%), emotional instability (3.0% vs. 0.2%), hostility (3.3% vs. 0.9%), and nervousness (7.3% vs. 1.8%). PBAR more common in epilepsy compared to non-epilepsy (cognition/anxiety) (<italic>p</italic> = 0.022).</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">de la Loge et al. 2010 [<xref ref-type="bibr" rid="B59">59</xref>]</td>
<td align="center" colspan="1" rowspan="1">RCT, <italic>t</italic> = 12 weeks</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 98 (4–16 years), of which 64 used LEV as add-on and 34 used placebo</td>
<td align="center" colspan="1" rowspan="1">Significant difference in total problem score between LEV (worsened) vs. placebo (improved). Significant worsening of aggression (LEV vs. placebo; <italic>p</italic> = 0.013). Based on questionnaires.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Dinkelacker et al. 2003 [<xref ref-type="bibr" rid="B30">30</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case series, <italic>t</italic> = 19 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 33 adults with epilepsy</td>
<td align="center" colspan="1" rowspan="1">33 patients that experienced irritability or aggression (representing 3.5% of all patients treated with LEV, vs. &lt;1% not on LEV). 24 patients: moderate or transient irritability, of which 10 had to reduce dose or discontinue. Nine (8 males) had severe aggressive symptoms; two of them required acute psychiatric intervention.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">French et al. 2001 [<xref ref-type="bibr" rid="B60">60</xref>]</td>
<td align="center" colspan="1" rowspan="1">Review article, <italic>t</italic> = &gt;3 years</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 3347 adults (healthy subjects and patients with epilepsy or anxiety)</td>
<td align="center" colspan="1" rowspan="1">PBAR in 13% of 769 patients with epilepsy using LEV in placebo-controlled studies (placebo: 6%). 6% (placebo: 4.1%) of elderly and 5.1% (placebo: 5.5%) of patients with anxiety reported PBAR.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Guilfoyle et al. 2017 [<xref ref-type="bibr" rid="B61">61</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = 1 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 335 children (mean age: 8.9 years) with newly diagnosed epilepsy, of which 37% started with LEV</td>
<td align="center" colspan="1" rowspan="1">Increased frequency of PBAR with any AED. LEV among those AEDs with the highest frequency.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Halma et al. 2014 [<xref ref-type="bibr" rid="B62">62</xref>]</td>
<td align="center" colspan="1" rowspan="1">Meta-analysis</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 727 (1 month–18 years) with epilepsy using LEV as monotherapy or add-on. 13 studies in total</td>
<td align="center" colspan="1" rowspan="1">Three RCTs: hostility (7.3%), nervousness (6.1%), and aggression (4.9%). Significantly increased risk for these adverse reactions (relative risk: 2.2 vs. placebo; 95% KI: 1.4–3.4). Ten observational studies: worsened and improved behavior with LEV. Add-on therapy associated with irritability (4.7%), hyperexcitability (4.4%), and aggression (2.7%); monotherapy associated with general behavior problems (19%) and irritability (2.6%).</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Helmstaedter et al. 2008 [<xref ref-type="bibr" rid="B63">63</xref>]</td>
<td align="center" colspan="1" rowspan="1">Interview-based, <italic>t</italic> = 2.3–5 years</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 466, of which 288 used LEV (men age: 38 years), 135 relatives, and 43 controls (using different AEDs)</td>
<td align="center" colspan="1" rowspan="1">37% reported a negative behavior change, of which aggression was most frequent.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Kanemura et al. 2014 [<xref ref-type="bibr" rid="B64">64</xref>]</td>
<td align="center" colspan="1" rowspan="1">Cohort study, <italic>t</italic> = 12 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 12 children (mean age: 10.3 years) with epilepsy and pervasive developmental disorder</td>
<td align="center" colspan="1" rowspan="1">Of eight patients with improved seizure control, six had &gt;50% reduction in panic episodes or aggression.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Kang et al. 2013 [<xref ref-type="bibr" rid="B51">51</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = 29.3 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 568 (mean age: 33 years) using LEV in mono- or polytherapy</td>
<td align="center" colspan="1" rowspan="1">Behavioral adverse reactions in up to 24%, of which irritability was most frequent.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Kowski et al. 2016 [<xref ref-type="bibr" rid="B65">65</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = 3 years</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 841 patients with epilepsy (mean age: 44.7 years), of which 438 used monotherapy (different AEDs)</td>
<td align="center" colspan="1" rowspan="1">LEV with the highest frequency of anger, aggression, nervousness, and agitation</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Labiner et al. 2009 [<xref ref-type="bibr" rid="B39">39</xref>]</td>
<td align="center" colspan="1" rowspan="1">RCT, <italic>t</italic> = 20 weeks</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 268 patients with epilepsy (&gt;16 years) of which 132 used LTG and 136 used LEV as add-on</td>
<td align="center" colspan="1" rowspan="1">Patients on LEV: worsened anger-aggression subscore, while patients on LTG improved each week.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lee et al. 2011 [<xref ref-type="bibr" rid="B33">33</xref>]</td>
<td align="center" colspan="1" rowspan="1">Cohort study, <italic>t</italic> = 24 weeks</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 71 patients with epilepsy (mean age: 35.4 years)</td>
<td align="center" colspan="1" rowspan="1">Improvement of anxiety symptoms with LEV, but five patients (6.5%) discontinued LEV due to PBAR (nervousness, irritability, anxiety, hostility, depression, suicidal ideation, and attempted suicide).</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mbizvo et al. 2014 [<xref ref-type="bibr" rid="B66">66</xref>]</td>
<td align="center" colspan="1" rowspan="1">Meta-analysis</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 1861 children and adults, 11 studies in total</td>
<td align="center" colspan="1" rowspan="1">Agitation in 0.82% on LEV vs. 0.14% on placebo. Irritability in 0.46% vs. 0% on placebo.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mula et al. 2003 [<xref ref-type="bibr" rid="B52">52</xref>]</td>
<td align="center" colspan="1" rowspan="1">Cohort study, <italic>t</italic> = 8.3 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 517 patients (mean age: 35.6 years) using LEV as add-on</td>
<td align="center" colspan="1" rowspan="1">PBAR in 10%, of which aggression was most frequent (3.5%).</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mula et al. 2004 [<xref ref-type="bibr" rid="B31">31</xref>]</td>
<td align="center" colspan="1" rowspan="1">Cohort study, <italic>t</italic> = 8.3 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 118 patients with epilepsy and learning disabilities (mean age: 30.6 years)</td>
<td align="center" colspan="1" rowspan="1">PBAR in 15 patients (12.7%). Aggression most common (9 patients; 7,6%). Two patients (1.7%) experienced agitation, anger, and hostility.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mula et al. 2007 [<xref ref-type="bibr" rid="B67">67</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = 2 years</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 108 patients with epilepsy (mean age: 37.9 years) using LEV and TPM (not simultaneously)</td>
<td align="center" colspan="1" rowspan="1">PBAR in 13%.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mula et al. 2015 [<xref ref-type="bibr" rid="B68">68</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, interview</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 163 (mean age: 42 years)</td>
<td align="center" colspan="1" rowspan="1">9.8% reported that aggressive behavior «always» was a problem.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Schiemann-Delgado et al. 2012 [<xref ref-type="bibr" rid="B69">69</xref>]</td>
<td align="center" colspan="1" rowspan="1">RCT, <italic>t</italic> = 48 weeks</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 103 (4–16 years) of which 80 were from the de la Loge et al. (2010) study</td>
<td align="center" colspan="1" rowspan="1">No difference in score for behavior/aggression (LEV vs. placebo). Aggression occurred in 7.8%, irritability in 7.8% [sic], abnormal behavior in 3.9%.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Schoenberg et al. 2017 [<xref ref-type="bibr" rid="B70">70</xref>]</td>
<td align="center" colspan="1" rowspan="1">RCT, <italic>t</italic> = 10 weeks</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 20 healthy elderly subjects, (mean age: 72.4 years) of which LEV: 9 and placebo: 11</td>
<td align="center" colspan="1" rowspan="1">LEV well tolerated regarding cognition, mood, and balance, but increased general tendency to feeling irritated (<italic>p</italic> = 0.029 vs. placebo).</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Shukla et al. 2016 [<xref ref-type="bibr" rid="B71">71</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = 2.5 years</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 445 patients with epilepsy (mean age: 21 years) using LEV (114), OXC (151), or VPA (134), of which 292 were included</td>
<td align="center" colspan="1" rowspan="1">PBAR in 43 patients (irritability, compulsive symptoms, aggression, psychosis). 23 (20.2%) used LEV. LEV discontinued in 10 patients (9%).</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Tekgul et al. 2016 [<xref ref-type="bibr" rid="B49">49</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control,<break></break><italic>t</italic> = ≥12 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 351 (6 months–18 years: mean age: 9.9 years) using LEV in monotherapy</td>
<td align="center" colspan="1" rowspan="1">PBAR in 87%. Irritability (67%), hyperactivity (8%), and disturbed behavior (5%) were most common.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Weintraub et al. 2007 [<xref ref-type="bibr" rid="B27">27</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = 13 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 1394 of which 521 patients (mean age: 43 years) used LEV</td>
<td align="center" colspan="1" rowspan="1">LEV with highest incidence (16%) of PBAR, leading to a discontinuation in 8%. Irritability in 9%, disturbed behavior in 3.5%.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">White et al. 2003 [<xref ref-type="bibr" rid="B53">53</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = 25 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 553 (mean age: 41.4 years)</td>
<td align="center" colspan="1" rowspan="1">7% discontinued LEV due to PBAR, mainly depression, and irritability. 1.8% were evaluated as a potential threat for themselves or others.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Wieshmann and Baker 2013 [<xref ref-type="bibr" rid="B72">72</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, interview</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 459 (mean age: 41.6 years) of which 418 have epilepsy and 41 controls. 158 used LEV in monotherapy or add-on, 260 used other AEDs</td>
<td align="center" colspan="1" rowspan="1">49% of LEV users reported anger as a problem, vs. 3% using other AEDs, and 7% of controls.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Wieshmann and Baker 2017 [<xref ref-type="bibr" rid="B73">73</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, interview</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 380 of which 329 (mean age: 39.8 years) have epilepsy using CBZ, VPA, LTG, or LEV in monotherapy, and 51 healthy controls</td>
<td align="center" colspan="1" rowspan="1">CNS-related adverse reactions more common with CBZ, VPA, LTG, and LEV vs. controls. Anger significantly more frequent with LEV (54% vs. 34% on CBZ, 33% on VPA, 31% on LTG, and 6% in controls).</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>RCT: randomized controlled trial, t: observation time; PBAR: psychiatric and/or behavioral adverse reactions; CBZ: carbamazepine; LEV: levetiracetam; LTG: lamotrigine; OXC: oxcarbazepine; PGB: pregabalin; TPM: topiramate; VPA: valproate; ZNS: zonisamide.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tab3" orientation="portrait" position="float">
<label>Table 3</label>
<caption>
<p>Studies reporting psychiatric and behavioral adverse reactions to perampanel.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Study</th>
<th align="center" colspan="1" rowspan="1">Study design</th>
<th align="center" colspan="1" rowspan="1">Study population</th>
<th align="center" colspan="1" rowspan="1">Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Biro et al. 2015 [<xref ref-type="bibr" rid="B35">35</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = 16 weeks–18 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 58 (mean age: 10.5 years) treated with PER</td>
<td align="center" colspan="1" rowspan="1">Aggression in 8 patients (13.8%).</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Chung et al. 2017 [<xref ref-type="bibr" rid="B43">43</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = 29–142 weeks</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 1643 patients (≥12 years) with epilepsy using PER in monotherapy or with LEV and/or TPM</td>
<td align="center" colspan="1" rowspan="1">PER with increased risk of PBAR (incl. aggression, hostility, irritability, and anger). Occurrence of hostility and aggression independent of cotreatment with LEV or TPM.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Coyle et al. 2014 [<xref ref-type="bibr" rid="B74">74</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = 19 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 47 patients with epilepsy (mean age: 31 years)</td>
<td align="center" colspan="1" rowspan="1">PBAR most common reason for discontinuation (aggression: <italic>n</italic> = 2; suicidal ideation <italic>N</italic> = 2; both combined: <italic>n</italic> = 1).</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">De Liso et al. 2016 [<xref ref-type="bibr" rid="B44">44</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = 7 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 62 children/adolescents (mean age: 14.2 years) using PER as add-on</td>
<td align="center" colspan="1" rowspan="1">PBAR in 19 patients (30.6%), including irritability (<italic>n</italic> = 7; 11.3%) and aggression (<italic>n</italic> = 3; 4.8%).</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Dolton and Choudry 2014 [<xref ref-type="bibr" rid="B75">75</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case report, <italic>t</italic> = &gt;6 months</td>
<td align="center" colspan="1" rowspan="1">1 patient (37 years) with epilepsy, Tourette's, moderately reduced cognitive function and demanding behavior</td>
<td align="center" colspan="1" rowspan="1">Add-on treatment with 8 mg PER improved seizure control but worsened aggressive behavior which resulted in institutionalization of the patient.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ettinger et al. 2015 [<xref ref-type="bibr" rid="B34">34</xref>]</td>
<td align="center" colspan="1" rowspan="1">Review of safety in phase I, II, and III clinical studies</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 9420 (12–&gt;65 years) with epilepsy, Parkinson's, pain, MS, or migraine who received either PER or placebo</td>
<td align="center" colspan="1" rowspan="1">Higher incidence of aggression and hostility for PER vs. placebo in “narrow” and “broad” questionnaires (narrow: PER 3.0% vs. placebo 0.7%; broad: 11.8% vs. 5.7%), but not increased in non-epilepsy disorders.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">French et al. 2015 [<xref ref-type="bibr" rid="B76">76</xref>]</td>
<td align="center" colspan="1" rowspan="1">RCT, <italic>t</italic> = 32–54 weeks</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 162 patients (man age: 28.4 years) with generalized epilepsy, of which PER: 81 and placebo: 81</td>
<td align="center" colspan="1" rowspan="1">Irritability was the only individual adverse reaction with incidence ≥5% (PER: 11.1% vs. placebo 3.7%). Combined incidence of hostility and aggression: PER 18.5% vs. placebo 4.9%.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Huber and Schmid 2017 [<xref ref-type="bibr" rid="B37">37</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = 2 years</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 26 patients (mean age: 30 years) with epilepsy and cognitive impairment of various degrees</td>
<td align="center" colspan="1" rowspan="1">PBAR in 50%, incl. irritability, aggression, increased sensitivity, and suicidal ideation/acts. This was also the main reason for discontinuation of PER.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Krauss et al. 2014 [<xref ref-type="bibr" rid="B77">77</xref>]</td>
<td align="center" colspan="1" rowspan="1">RCT, <italic>t</italic> = 1.5–&gt;2 years</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 1216 patients (≥12 years) with epilepsy, using 1–3 AEDs and PER as add-on</td>
<td align="center" colspan="1" rowspan="1">Irritability in 11.5% and aggression in 5.1%, leading to discontinuation of PER in 1.3% and 0.4%, respectively. 3.9% had ≥1 serious PBAR, of which 0.2% agitation, 0.2% abnormal behavior, and 1% aggression.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lagae et al. 2016 [<xref ref-type="bibr" rid="B78">78</xref>]</td>
<td align="center" colspan="1" rowspan="1">RCT, <italic>t</italic> = 20 weeks</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 133 (12–17 years) with epilepsy (PER: 85 and placebo: 48)</td>
<td align="center" colspan="1" rowspan="1">No difference in total score (behavior and competence) between PER and placebo, but aggression and hostility in 15 patients (17.6%) on PER vs. 2 (4.2%) on placebo.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Rosenfeld et al. 2015 [<xref ref-type="bibr" rid="B45">45</xref>]</td>
<td align="center" colspan="1" rowspan="1">RCT, <italic>t</italic> = 25–29 weeks</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 143 (12–17 years) with epilepsy of which PER: 98 and placebo: 45</td>
<td align="center" colspan="1" rowspan="1">Aggression in 8.2% (vs. 0% on placebo). Aggression was one of the most common reasons (6.6%) for dose changes or discontinuation of PER</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Rugg-Gunn 2014 [<xref ref-type="bibr" rid="B46">46</xref>]</td>
<td align="center" colspan="1" rowspan="1">Review article, <italic>t</italic> = ≥19 weeks</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 1450 patients of which 1008 on PER and 442 on placebo</td>
<td align="center" colspan="1" rowspan="1">Higher frequency of PBAR with PER, particularly irritability and aggression. Frequency of serious PBAR reported as low, but 3 cases of aggression and 1 of suicidal ideation.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Snoeijen-Schouwenaars et al. 2017 [<xref ref-type="bibr" rid="B36">36</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = 12 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 62 patients (mean age: 27.4 years) with epilepsy and intellectual disability</td>
<td align="center" colspan="1" rowspan="1">Behavioral adverse reactions in 40.3%. Most common: aggression, agitation, disturbing behavior, and mood symptoms.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Steinhoff et al. 2013 [<xref ref-type="bibr" rid="B47">47</xref>]</td>
<td align="center" colspan="1" rowspan="1">RCT, <italic>t</italic> = 25 weeks</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 1478 of which PER: 1038 (mean age: 34.8 years) or placebo: 442 (mean age: 34.3 years)</td>
<td align="center" colspan="1" rowspan="1">Irritability in 11.8% on 12 mg PER (vs. 2.9% on placebo and 3.9–6.7% on 2–8 mg PER). Aggression in 3% on 12 mg PER (vs. 1% on placebo, 1% on 4 mg PER, and 2% on 8 mg PER). Hostility or aggression in 5% (4 mg), 12% (8 mg), and 20% (12 mg) on PER, vs. 6% on placebo</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Steinhoff et al. 2014 [<xref ref-type="bibr" rid="B79">79</xref>]</td>
<td align="center" colspan="1" rowspan="1">Cohort study, <italic>t</italic> = ≥6 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 281 patients (≥12 years) with focal seizures</td>
<td align="center" colspan="1" rowspan="1">Aggression in 2.8%, irritability in 2.1%.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Wehner et al. 2017 [<xref ref-type="bibr" rid="B80">80</xref>]</td>
<td align="center" colspan="1" rowspan="1">Cohort study, <italic>t</italic> = 38–42 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 391 patients (≥17 years) using PER as add-on</td>
<td align="center" colspan="1" rowspan="1">Negative effect on mental health in 137 patients (36%), incl. worsened mood, increased irritability and demanding behavior</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Zaccara et al. 2013 [<xref ref-type="bibr" rid="B48">48</xref>]</td>
<td align="center" colspan="1" rowspan="1">Meta-analysis</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 3947 patients with epilepsy or Parkinson's, of which 2627 used PER in a total of 9 RCTs</td>
<td align="center" colspan="1" rowspan="1">Irritability and aggression with a PER dose of 12 mg/day.<break></break>Overall tolerability was better in epilepsy compared to Parkinson's, but patients with Parkinson's were older.</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>RCT: randomized controlled trial, t: observation time; PBAR: psychiatric and/or behavioral adverse reactions; LEV: levetiracetam; PER: perampanel; TPM: topiramate.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tab4" orientation="portrait" position="float">
<label>Table 4</label>
<caption>
<p>Studies reporting psychiatric and behavioral adverse reactions to topiramate.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Study</th>
<th align="center" colspan="1" rowspan="1">Study design</th>
<th align="center" colspan="1" rowspan="1">Study population</th>
<th align="center" colspan="1" rowspan="1">Main findings</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Chen et al. 2017 [<xref ref-type="bibr" rid="B18">18</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = ≥1 years</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 4085 adults (mean age: 41 years) with epilepsy on ≥1 AED, of which TPM: 639</td>
<td align="center" colspan="1" rowspan="1">PBAR in 17.2%, leading to dose reduction or discontinuation in 13.8% (all patients) and 6.3% (TPM users).</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Chung et al. 2007 [<xref ref-type="bibr" rid="B50">50</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = 2 years</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 828 adults (mean age 38.5 years) on different AEDs (LEV: 196, LTG: 251, OXC: 97, TPM: 156, ZNS: 128)</td>
<td align="center" colspan="1" rowspan="1">TPM with the highest rate of discontinuation (55.8%), but only few due to PBAR (5 of 156 patients).</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Endoh et al. 2012 [<xref ref-type="bibr" rid="B54">54</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = 17.6 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 58 children with epileptic spasms, of which 33 used TPM</td>
<td align="center" colspan="1" rowspan="1">5 of 33 patients (15.2%) developed irritability.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Grosso et al. 2005 [<xref ref-type="bibr" rid="B81">81</xref>]</td>
<td align="center" colspan="1" rowspan="1">Cohort study, <italic>t</italic> = 11 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 59 children &lt; 2 years (mean age: 13 months) on TPM</td>
<td align="center" colspan="1" rowspan="1">Irritability is one of the most common adverse reactions.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Kanner et al. 2003 [<xref ref-type="bibr" rid="B82">82</xref>]</td>
<td align="center" colspan="1" rowspan="1">Cohort study, <italic>t</italic> = 10.5 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 596 patients (mean age: 36.1 years) with epilepsy using TPM as monotherapy or add-on</td>
<td align="center" colspan="1" rowspan="1">PBAR in 12.6%, incl. aggression (10.7%), irritability (5.7%), and depression (5%). TPM discontinued in 27% with these adverse reactions.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lee et al. 2011 [<xref ref-type="bibr" rid="B55">55</xref>]</td>
<td align="center" colspan="1" rowspan="1">Cohort study, <italic>t</italic> = 17.2 weeks</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 28 children (2-18 months) with infantile spasms using TPM</td>
<td align="center" colspan="1" rowspan="1">Irritability in 4 patients (14.3%; most common adverse reaction).</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mula et al. 2003 [<xref ref-type="bibr" rid="B38">38</xref>]</td>
<td align="center" colspan="1" rowspan="1">Cohort study, <italic>t</italic> = ≥6 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 431 patients (mean age 35.8 years) with epilepsy using TPM</td>
<td align="center" colspan="1" rowspan="1">PBAR in 24% (aggression: 5.6%).</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mula and Trimble 2003 [<xref ref-type="bibr" rid="B56">56</xref>]</td>
<td align="center" colspan="1" rowspan="1">Cohort study, <italic>t</italic> = ≥6 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 103 patients on TPM</td>
<td align="center" colspan="1" rowspan="1">Mood symptoms in almost half of patients. Aggression is the second most common (23%), resolved after dose reduction or discontinuation of TPM.</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mula et al. 2007 [<xref ref-type="bibr" rid="B67">67</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = 2 years</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 108 patients with epilepsy, treated with LEV and TPM (consecutively)</td>
<td align="center" colspan="1" rowspan="1">PBAR in 30%</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Reith et al. 2003 [<xref ref-type="bibr" rid="B83">83</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = 309 days</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 159&lt; 18 years (mean age: 8.1 years) with epilepsy using TPM; follow-up of <italic>n</italic> = 127 of these</td>
<td align="center" colspan="1" rowspan="1">Aggression or psychosis treatment-limiting in 10 of 127 patients (7.9%).</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Weintraub et al. 2007 [<xref ref-type="bibr" rid="B27">27</xref>]</td>
<td align="center" colspan="1" rowspan="1">Case-control, <italic>t</italic> = 13 months</td>
<td align="center" colspan="1" rowspan="1">
<italic>n</italic> = 1394 of which 112 patients (mean age: 41 years) used TPM</td>
<td align="center" colspan="1" rowspan="1">PBAR in 6.3% on TPM, which was lower than the mean frequency of all AEDs (8.4%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>RCT: randomized controlled trial, t: observation time; PBAR: psychiatric and/or behavioral adverse reactions; LEV: levetiracetam; LTG: lamotrigine; OXC: oxcarbazepine; TPM: topiramate, ZNS: zonisamide.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>